#### 1 Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer's disease

- 2 Elisabet A. Frick<sup>1</sup>, Valur Emilsson<sup>1,2</sup>, Thorarinn Jonmundsson<sup>2</sup>, Anna E. Steindorsdottir<sup>2</sup>, Erik C. B.
- Johnson<sup>3,4</sup>, Raquel Puerta<sup>6</sup>, Eric B. Dammer<sup>3,5</sup>, Anantharaman Shantaraman<sup>3,5</sup>, Amanda Cano<sup>6,7</sup>, Mercè
- 4 Boada<sup>6,7</sup>, Sergi Valero<sup>6,7</sup>, Pablo García-González<sup>6,7</sup>, Elias F. Gudmundsson<sup>1</sup>, Alexander Gudjonsson<sup>1</sup>,
- 5 Joseph J. Loureiro<sup>8</sup>, Anthony P. Orth<sup>9</sup>, Nicholas T. Seyfried<sup>3,4</sup>, Allan I. Levey<sup>3,4</sup>, Agustin Ruiz<sup>6,7</sup>, Thor
- 6 Aspelund<sup>1,2</sup>, Lori L. Jennings<sup>8</sup>, Lenore J. Launer<sup>10</sup>, Valborg Gudmundsdottir<sup>\*1,2</sup>, Vilmundur Gudnason<sup>\*1,2</sup>
- 7 1 Icelandic Heart Association, Kopavogur, 200, Iceland
- 8 2 Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland
- 9 3 Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, 30329, GA, USA
- 10 4 Department of Neurology, Emory University School of Medicine, Atlanta, 30329, GA, USA
- 11 5 Department of Biochemistry, Emory University School of Medicine, Atlanta, 30329, GA, USA
- Research Center and Memory Clinic. Ace Alzheimer Center Barcelona Universitat Internacional de Catalunya, Barcelona,
   08028, Spain, Barcelona.
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III,
   Madrid, 28029, Spain.
- 16 8 Novartis Biomedical Research, Cambridge, 02139, MA, USA
- 17 9 Novartis Biomedical Research, San Diego, 10675, CA, USA
- 10 Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute
   on Aging, Bethesda, 20892, MD, USA
- 20
- 21 Correspondence: <a href="mailto:valborgg@hi.is">valborgg@hi.is</a>, <a href="mailto:v.gudnason@hjarta.is">v.gudnason@hjarta.is</a>
- 22 Summary
- 23 The current demand for early intervention, prevention, and treatment of late onset Alzheimer's disease
- 24 (LOAD) warrants deeper understanding of the underlying molecular processes which could contribute to
- 25 biomarker and drug target discovery. Utilizing high-throughput proteomic measurements in serum from
- a prospective population-based cohort of older adults (n=5,294), we identified 303 unique proteins
- associated with incident LOAD (median follow-up 12.8 years). Over 40% of these proteins were
- associated with LOAD independently of APOE- $\varepsilon 4$  carrier status. These proteins were implicated in
- 29 neuronal processes and overlapped with protein signatures of LOAD in brain and cerebrospinal fluid. We
- 30 found 17 proteins which LOAD-association was strongly *dependent* on *APOE*-ε4 carrier status. Most of
- 31 them showed consistent associations with LOAD in cerebrospinal fluid and a third had brain-specific gene
- 32 expression. Remarkably, four proteins in this group (TBCA, ARL2, S100A13 and IRF6) were
- downregulated by APOE- $\varepsilon$ 4 yet upregulated as a consequence of LOAD as determined in a bi-directional
- 34 Mendelian randomization analysis, reflecting a potential response to the disease onset. Accordingly, the
- 35 direct association of these proteins to LOAD was reversed upon APOE-ε4 genotype adjustment, a finding
- 36 which we replicate in an external cohort (n=719). Our findings provide an insight into the dysregulated

37 pathways that may lead to the development and early detection of LOAD, including those both

independent and dependent on *APOE*-ε4. Importantly, many of the LOAD-associated proteins we find in

39 the circulation have been found to be expressed - and have a direct link with AD - in brain tissue. Thus,

40 the proteins identified here, and their upstream modulating pathways, provide a new source of

41 circulating biomarker and therapeutic target candidates for LOAD.

42 **Keywords:** Alzheimer's disease, APOE, Proteomics, Mendelian randomization, Longitudinal study, Cross-

43 sectional study, CSF, Brain, Network.

### 44 Introduction

Alzheimer's disease (AD) is the most common cause of dementia, accounting for up to 80% of all
dementia cases<sup>1</sup>, of which *late onset* Alzheimer's disease (LOAD) is most common<sup>2</sup>. As of 2022,

47 approximately 55 million individuals worldwide had dementia, representing 1 out of 9 people aged 65

48 and over<sup>3</sup>. While promising advances have been made in amyloid-targeting therapeutic options for early-

49 stage LOAD<sup>4,5</sup>, they still have limited benefit and identification of additional risk pathways that can be

50 used for early detection and intervention is highly needed. To meet these demands, a variety of

51 biologically relevant circulating molecules have been broadly associated with LOAD risk. The proteome in

52 particular has the potential to reveal circulating markers of disease-related molecular pathways from

53 different tissues, and studies assessing the circulating proteomic signatures between non-demented

54 older adults and individuals suffering from LOAD have been described<sup>6–17</sup>. Modest sample sizes, low-

55 throughput proteomics and lack of longitudinal measurements have, however, been limiting factors in

these studies. However, a recent large-scale longitudinal study identified promising blood-based markers

57 for all-cause incident dementia although it is unknown how specific the results are to LOAD<sup>18</sup>.

58 Information on the global circulating proteomic profile preceding the onset of LOAD, and how well it

reflects AD-related processes in brain and CSF, is thus scarce.

Alzheimer's disease has a considerable genetic component, and both common<sup>19</sup> and rare risk
variants have been identified<sup>20</sup>, of which the strongest effects are conferred by variants in the wellknown apolipoprotein E (*APOE*) gene. Approximately 25% of the general population carries the *APOE-ε4*variant while it is present in over 50% of AD cases<sup>21,22</sup>. The *APOE-ε4* allele increases the risk of LOAD by
threefold in heterozygous carriers and up to twelvefold in homozygous carriers<sup>23</sup>. Although the link
between the ε4 allele and LOAD has been extensively researched, light has yet to be shed on the precise
mechanism by which the *APOE* gene affects LOAD onset and/or progression. Importantly, recent large-

scale proteogenomic studies have consistently established the APOE locus as a protein-regulatory
hotspot, regulating levels of hundreds of proteins in both circulation<sup>24-27</sup> and cerebrospinal fluid
(CSF)<sup>28,29</sup>. Yet, it remains unknown to what extent these proteins relate to LOAD and if they can provide
new information on the mechanisms through which APOE-ɛ4 mediates it risk. Identifying LOADassociated circulatory proteins and whether their association is APOE-dependent or independent is
crucial for the understanding of AD more generally as well as for gaining insight into potential pathways
suitable for targeting in personalized treatment.

74 The current study tests the hypotheses that specific proteomic signatures in the circulation 75 precede LOAD diagnosis and can reflect dysregulated biological pathways in the brain and CSF. 76 Furthermore, we expect that some of these protein signatures may be affected by the APOE- $\varepsilon 4$  genotype 77 and can thus provide molecular read-out of pathways directly affected by APOE- $\varepsilon 4$ . To address these 78 hypotheses, we used a high throughput aptamer-based platform to characterize 4,137 serum proteins in 79 5,294 participants of the population-based Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-RS)<sup>30</sup> to identify protein signatures of incident LOAD (events occurring during follow-up) and prevalent 80 81 LOAD, taking an unbiased, longitudinal, and cross-sectional approach to the discovery of potential 82 biomarkers for LOAD (Figure 1). Considering APOE's protein-regulatory influence and how it may impact 83 the way that serum-proteins are associated with LOAD, we disentangled the LOAD protein signature into 84 APOE- $\varepsilon 4$  dependent and independent components, by identifying proteins whose LOAD-association is 85 largely attenuated upon conditioning on APOE-ɛ4 carrier status. We compared the serum protein signature of LOAD to those observed in cerebrospinal fluid (CSF) and brain and finally, used genetic 86 87 variation as anchors to determine the potential causal direction between serum proteins and disease 88 state.

89

## 90 Results

The AGES study cohort. This prospective population-based study was based on 5,127 participants free of
 dementia at baseline, after the exclusion of 163 individuals with prevalent non-AD dementia, and 167
 individuals with prevalent LOAD. During a potential follow-up of 12.8 years (median), 655 individuals
 were diagnosed with incident LOAD, with the last individual being diagnosed 16 years from baseline.
 Participants with incident LOAD were older at entry, were more likely to carry an APOE-ε4 allele, had
 lower BMI, and had lower education levels compared to healthy individuals (Supplementary Table 1). See
 Figure 1 for study overview.

98 Serum protein profile of incident LOAD in AGES. To investigate the LOAD-associated circulatory 99 proteomic patterns which occur prior to disease onset, we used Cox proportional hazards models and 100 found 320 aptamers (303 proteins) to be significantly (FDR < 0.05) associated with incident LOAD 101 diagnosis after adjusting for age and sex (model 1), with hazard ratios (HRs) ranging from 0.78 for TBCA 102 to 1.47 for NTN1 (Figure 2D, Supplementary Table 2). To account for variability related to APOE- $\epsilon$ 4 103 carrier status, we adjusted for the genotype in an additional model (model 2, Supplementary Table 2), 104 which resulted in 140 significant aptamers (130 proteins, HR 0.79 (CD4) – 1.25 (CGA/FSHB), FDR < 0.05) 105 (Figure 2E), all of which overlapped with model 1 (Figure 2F). When comparing the two models, 43% of 106 the serum proteins remained significant after  $APOE - \varepsilon 4$  adjustment, indicating that their LOAD 107 association is independent of the APOE- $\varepsilon 4$  genotype (Table 1). Adjusting for additional AD risk factors 108 and eGFR (see Methods) retained 38 significant LOAD-associated aptamers (35 proteins, HR 0.80 (CD4) -109 1.26 (SMOC1), FDR < 0.05) (model 3, Supplementary Table 2), which may reflect specific processes 110 affecting risk of LOAD but not driven by currently established risk factors.

111 As hazard ratio variability can arise with lengthy follow-up time, secondary analyses were 112 implemented with a 10-year follow-up cut-off, which revealed mostly overlapping results 113 (Supplementary Note 1, Supplementary Tables 3 and 4, Supplementary Figure 1). We did however detect 114 protein associations specific to the shorter follow-up time, which potentially reflect processes that take 115 place closer to the LOAD diagnosis. As there may be further differences in proteomic profiles depending 116 on whether protein sampling occurred before or after LOAD diagnosis, we additionally considered the 117 protein profile of the 167 individuals with prevalent LOAD at baseline (Supplementary Note 2, 118 Supplementary Figure 2A-C, Supplementary Tables 5-7). Interestingly, many of the proteins associated 119 with increased risk of incident LOAD showed the opposite direction of effect for prevalent LOAD, 120 although generally not statistically significant (Supplementary Figure 2D). These contrasting results

suggest an important temporal element in the LOAD-associated proteome. In total there were 346
aptamers (329 unique proteins) associated with LOAD when all outcomes (incident and prevalent LOAD),
follow-up times and models were considered (Supplementary Tables 2, 3, 5, 6, and 7).

124 To evaluate which biological processes are reflected by the overall incident LOAD-associated 125 protein signature in AGES, we performed a gene set enrichment analysis (GSEA). The strongest 126 enrichment for protein associations in model 1 was observed for gene ontology (GO) terms related to 127 neuron development and morphogenesis (Figure 2H-I, Supplementary Table 8). The proteins driving the 128 enrichment included Neural Cell Adhesion Molecules 1 and 2 (NCAM1, and NCAM2), Netrin 1 (NTN1), 129 Contactin 1 (CNTN1), Neuropilin 1 (NRP1), Fibronectin Leucine Rich Transmembrane Protein 2 (FLRT2), 130 Matrix Metallopeptidase 2 (MMP2) and Cell Adhesion Molecule L1 like (CHL1). GSEA of the protein 131 profiles of model 2, where APOE-E4 carrier status was adjusted for, showed similar enrichment results 132 (Supplementary Table 8), demonstrating that these terms were mainly driven by the APOE- $\varepsilon 4$ 133 independent component of the LOAD-associated protein profile.

134 Serum proteins with APOE-dependent association to incident LOAD. As previously mentioned, 43% of 135 the protein associations with incident LOAD were independent of APOE- $\varepsilon 4$ . Of the remaining 57% that 136 were affected by APOE-E4 adjustment, we identified 17 proteins whose associations with incident LOAD 137 were particularly strongly affected by  $APOE - \varepsilon 4$  carrier status (Table 2, Figure 3A, Supplementary Figure 3, 138 Supplementary Table 2). These proteins, hereafter referred to as APOE-dependent proteins, were 139 defined as proteins significantly (FDR < 0.05) associated with incident LOAD in model 1 but whose 140 nominal significance was attenuated (P > 0.05) or direction of effect changed upon APOE- $\varepsilon 4$  adjustment 141 in model 2. These APOE-dependent proteins included those with the strongest associations to LOAD 142 prior to adjusting for the APOE- $\varepsilon 4$  allele (Figure 2A, D). The levels of the APOE protein itself were not 143 associated with either incident or prevalent LOAD. Figure 3B shows the intra-correlations among the 17 144 APOE-dependent proteins. All the 17 APOE-dependent proteins were strongly regulated by the APOE- $\epsilon 4$ 145 allele (Figure 3C, Table 2, Supplementary Figure 4, Supplementary Table 9), with the  $\varepsilon 4$  allele increasing 146 the levels of five of the proteins and decreasing the levels of the other 12. Accordingly, we observed that 147 increased levels of the five APOE-E4 upregulated proteins and decreased levels of the 12 APOE-E4 148 downregulated proteins were also associated with higher risk of LOAD, yielding a hazard ratio above and 149 below one, respectively (Figure 3D). As per definition, most of the APOE-dependent proteins lost 150 significance upon APOE-ɛ4 adjustment yet interestingly, the direction of effect inverted for five proteins 151 after APOE-ε4 adjustment (ARL2, IRF6, NEFL, S100A13, TBCA) (Figure 3E).

152 The HR conferred by APOE- $\varepsilon 4$  for incident LOAD in AGES was 2.1 (P = 1.23e-27) per each  $\varepsilon 4$ 153 allele. To evaluate if any of the 17 APOE-dependent proteins might mediate the effect of APOE- $\varepsilon 4$  on 154 incident LOAD, we considered the change in HR for APOE- $\varepsilon 4$  on risk of incident LOAD when adjusting for 155 individual proteins. We found that adjustment for most proteins resulted in a minor effect decrease, 156 suggesting they do not mediate the  $APOE-\varepsilon 4$  effect on LOAD (Supplementary Figure 5A). Intriguingly, 157 however, the adjustment for four proteins (NEFL, ARL2, TBCA and S100A13) caused an increase of ~10% 158 in APOE- $\varepsilon 4$  effect size (Supplementary Figure 5A-B). Thus, the effect of APOE- $\varepsilon 4$  on LOAD is partly masked by secondary opposing associations between these proteins and LOAD, which are further 159 160 explored below. The effect of APOE-E4 carrier status on LOAD risk was largely unchanged in a 161 multivariable model containing all 17 APOE-dependent proteins, thus not supporting a mediating effect 162 of these proteins for the LOAD risk conferred by APOE- $\varepsilon 4$  (base model: HR = 2.1, P = 1.23e-27, 163 multivariable model: HR = 2.2, P = 3.2e-10). However, although not direct mediators, the 17 proteins 164 could be blood-based readouts of a true mediator within tissue-specific pathological processes occurring 165 prior to LOAD diagnosis.

166 To map out potential tissues of origin for the circulating levels of the 17 APOE-dependent proteins, we considered gene expression data from the Human Protein Atlas<sup>31</sup>. We observed that five 167 168 (LRRN1, TMCC3, FAM159B, NEFL, GSTM1) of the APOE-dependent proteins had elevated gene 169 expression in brain compared to other tissues and additional two (IFIT2, NDE1) clustered with brain-170 specific genes (Table 2). Of the remaining APOE-dependent proteins, six were universally expressed, 171 including in brain tissue, and four were enriched in other tissues. We did not detect any significantly 172 enriched molecular signatures nor GO terms for the 17 APOE-dependent proteins (Supplementary Table 173 7). However, a network analysis of measured and inferred physical protein-protein interactions<sup>32</sup> 174 revealed that the APOE-dependent proteins interact directly with proteins involved in neuronal 175 response- and development, neuroinflammation and AD (Figure 4, Supplementary Table 10-12, 176 Supplementary Note 3).

Given the well-established relationship between APOE and cholesterol<sup>33</sup> we explored the potential effect of serum lipid levels on the association between LOAD and the 17 *APOE*-dependent proteins (Supplementary Table 13, Supplementary Figures 6-7, Supplementary Note 4). Our findings suggest that, while many of the *APOE*-dependent proteins are associated with cholesterol levels, it is not the driver of their link to LOAD.

182 External validation of protein associations with incident LOAD in the ACE cohort. We set to externally 183 evaluate our observations in an independent cohort, the ACE - Alzheimer Center Barcelona (n=1,341), 184 with SOMAscan platform (7k) measurements from plasma of individuals who were referred to the 185 center. The longitudinal component of ACE consists of individuals who had been diagnosed with mild 186 cognitive impairment (MCI) at the center and had been followed up. A total of 719 participants had 187 follow-up information and 266 converted to LOAD over a median follow-up of 3.14 years (Supplementary 188 Table 14). Despite the fundamentally different cohorts, with AGES being population-based and using the 5K SOMAscan platform and ACE being based on individuals with established symptoms and the 7K 189 190 SOMAscan platform, we replicated 36 protein associations with LOAD at nominal significance (P < 0.05) 191 in the smaller ACE cohort (Table 3, Figure 2F-G). Of those, 30 proteins were nominally significant in 192 model 1 with 97% being directionally consistent with the observations in AGES (Figure 2F). In model 2, 21 193 proteins were nominally significant, 86% of which were directionally consistent (Figure 2G). After 194 multiple testing correction, seven proteins remained statistically significant (FDR < 0.05), all of which 195 were directionally consistent (Table 3, Figure 2F-G). Six were statistically significant (FDR < 0.05) in model 196 1 (NEFL, LRRN1, TBCA, CTF1, C1orf56 and TIMP4) and one in model 2 (S100A13) (Supplementary Table 197 9). Of all 332 tested aptamers, 213 (64%) were directionally consistent regardless of significance in 198 model 1 (Exact binomial test P = 2.0e-05) and 202 (61%) were directionally consistent in model 2 (Exact 199 binomial test P = 0.002), demonstrating an enrichment for consistency in direction of effect. The protein 200 associations replicated in the ACE cohort are of particular interest as they represent potentially clinically 201 relevant candidates for LOAD that are consistent in two different contexts, in both a general population 202 and a clinically derived symptomatic sample set. However, our results suggest that many of the proteins 203 that associate with long-term LOAD risk are not strongly associated with the conversion from MCI to AD, 204 which is further into the AD trajectory and may also explain the limited overlap between the proteins 205 associated with prevalent and incident LOAD in AGES.

## 206 External validation of reversed LOAD association conditional on APOE- $\varepsilon$ 4 for a subset of proteins.

207 Specifically considering the *APOE*-dependent proteins, the association between the *APOE*-ε4 allele and 208 the proteins was replicated for 13 of 17 proteins in the ACE cohort (Figure 3F). Furthermore, the change 209 in direction of effect for incident LOAD upon *APOE*-ε4 adjustment was replicated in the ACE cohort for 4 210 of 5 proteins (ARL2, NEFL, S100A13 and TBCA) (Figure 3G-H) (Supplementary Table 9), with even larger 211 effects observed in the ACE cohort compared to AGES in the *APOE*-ε4 adjusted model and three proteins 212 (ARL2, S100A13 and TBCA) becoming statistically significant (P < 0.05). Thus, the attenuation of the 213 primary LOAD associations for these proteins upon *APOE*-ε4 adjustment meet the criteria of *APOE*-ε4

dependence (see Methods). No significant interaction between protein and APOE-ε4 carrier status on AD
risk was observed in either the AGES or ACE cohorts. Taken together, our results show that these
proteins are strongly downregulated by APOE-ε4, and consequently show an inverse relationship with
incident LOAD, but when adjusting for the APOE-ε4 allele, their association to LOAD is still significant but
reversed – suggesting a secondary non-APOE-ε4-mediated process affecting these same proteins in
relation to LOAD in the opposite direction that is more strongly observed a cohort of individuals with
MCI than in the population-based AGES cohort.

221 Mendelian randomization to identify potential causal associations between proteins and LOAD. The proteins associated with LOAD could include proteins causally related to the disease, or proteins whose 222 223 serum level changes reflect a response to prodromal or genetic liability to LOAD. To test this hypothesis, 224 we performed a bi-directional two-sample MR analysis, including the targets of all 346 aptamers 225 associated with LOAD in our study. Genetic variant associations for serum protein levels were obtained from a catalog of cis-protein quantitative trait loci (pQTLs) from AGES<sup>24</sup> while variant associations with 226 227 LOAD were extracted from a recent GWAS on 39,106 clinically diagnosed LOAD cases, 46,828 proxy-LOAD and dementia cases and 401.577 controls of European ancestry<sup>19</sup>. In total, 117 (34%) of the LOAD-228 229 associated serum aptamers had cis-pQTLs that were suitable as genetic instruments and were included 230 in the protein-LOAD MR analysis (Supplementary Table 15).

231 In the forward MR analysis, two proteins, integrin binding sialoprotein (IBSP) and amyloid 232 precursor protein (APP), had support for causality (Supplementary Table 16). IBSP had a risk-increasing 233 effect for LOAD in both the causal (OR = 1.26, FDR = 0.03) and observational analysis (incident LOAD full 234 follow up, HR = 1.13, FDR = 0.04). APP had a protective effect for LOAD in both the causal (OR = 0.76, FDR 235 = 0.03) and observational analysis (incident LOAD full follow up, HR = 0.87, FDR = 0.047). Notably, while 236 not statistically significant, we observed suggestive support for a protective effect of genetically 237 determined serum levels of acetylcholinesterase (ACHE, OR = 0.92, P = 0.061), a target of clinically used therapeutic agent for dementia<sup>34</sup> (Supplementary Table 16, Supplementary Figure 8). In a forward MR 238 239 analysis of the APOE-dependent protein interaction partners, two proteins, APP and MAPK3, had support 240 for causality (Supplementary Tables 10-12, Supplementary Note 3).

As most of the observational protein associations in the current study were detected for incident LOAD, and thus reflect changes that take place before the onset of clinically diagnosed disease, it is unlikely that their levels and effects are direct downstream consequences of the disease after it reaches a clinical stage. However, they may reflect a response to a prodromal stage of the disease. We therefore

245 performed a reverse MR to test if the observed changes in serum protein levels are likely to occur 246 downstream of the genetic liability to LOAD, which may capture processes both at the prodromal and 247 clinical stage. The APOE locus is likely to have a dominant pleiotropic effect in the reverse MR analysis 248 (Supplementary Table 17, Supplementary Figure 9, Supplementary Note 5), as it has a disproportionately 249 strong effect on LOAD risk compared to all other common genetic variants, while also being a wellestablished pQTL trans-hotspot, affecting circulating levels of up to hundreds of proteins<sup>24,25,27</sup>. We 250 therefore performed the primary reverse MR analysis using only LOAD-associated genetic variants 251 252 outside of the APOE locus as instruments. We found two proteins (S100A13 and ARL2) that were 253 significantly (FDR < 0.05) affected by LOAD or its genetic liability (Supplementary Table 17, 254 Supplementary Figures 9-10). Interestingly, both were among the 17 previously identified APOE-255 dependent LOAD proteins, together with two additional proteins that were nominally significant in the 256 reverse MR (TBCA, P = 4.4e-4, FDR = 0.051 and IRF6, P = 7.9e-4, FDR = 0.055). Thus intriguingly, these 257 findings suggest that these four proteins are upregulated by LOAD, in contrast to the observed APOE-E4 258 downregulation of the same proteins (Figure 5). This supports our findings of competing biological 259 effects described above (Figure 3E, Supplementary Figure 5) and collectively our results indicate that 260 simultaneous opposing effects of APOE-E4 on one hand and LOAD on the other result in differential 261 regulation of these proteins in serum (Figure 5B).

262 We performed a replication analysis of the effect of  $APOE - \varepsilon 4$  on protein levels and the reverse 263 MR results for these four proteins using published protein GWAS summary statistics from two recent studies<sup>25,35</sup>. In the external datasets, the downregulation of all four proteins by APOE-E4 (as determined 264 265 by the rs429358 C allele) was replicated. In the reverse MR analysis (excluding the APOE locus), the 266 upregulation of protein levels by LOAD liability observed in AGES was also detected for two proteins 267 (S100A13 and TBCA) in both validation cohorts, reaching significance (P < 0.05) in the study by 268 Ferkingstad et al. (Supplementary Figure 11, Supplementary Table 18). While the two proteins changed 269 direction in a similar manner as in AGES, the effect size was considerably smaller in the validation 270 cohorts. Importantly, however, individuals in these two cohorts are much younger than those in AGES, 271 with mean ages of 55 and 48 years for the Ferkingstad et al. and Sun et al. studies, respectively, 272 compared to 76 years in AGES. Therefore, we conducted an age-stratified reverse MR analysis in AGES, 273 which showed a strong age-dependent effect, with a much larger effect of LOAD genetic liability on 274 protein levels in individuals over 80 years old compared to those younger than 80 years (Supplementary 275 Figure 11). The effect size in AGES individuals under 80 years old was in line with the effect observed in 276 the validation cohorts. Thus, if the upregulation of these proteins reflects a response to prodromal or

preclinical LOAD, an older cohort may be needed to detect an association of the same degree as we
found in AGES. However, the observed support in the validation cohorts for the discordant effects of *APOE* vs non-*APOE* LOAD-associated genetic variants on the same serum proteins strongly implicates
these proteins as directly relevant to LOAD, potentially as readouts of biological processes that are both
disrupted by *APOE*-ε4 and modulated in the opposite manner as a response to genetic predisposition to
LOAD or the disease onset in general.

283 Together, these results indicate that LOAD or its general genetic liability causally affects the 284 levels of some APOE-dependent proteins, but this effect is simultaneously masked by the strong effects 285 of the APOE locus in the other direction (Figure 5A). These outcomes strengthen results described above, 286 showing that the levels of these four proteins are strongly downregulated in APOE- $\varepsilon 4$  carriers and lower 287 levels of these proteins are therefore associated with increased risk of LOAD in an APOE-dependent 288 manner (Figure 5B). Simultaneously, the reverse MR analysis shows that the collective effect of the other 289 non-APOE LOAD risk variants is to upregulate the serum levels of these same proteins, possibly reflecting 290 a response mechanism to LOAD pathogenesis (Figure 5C). Again, this is in line with the observational 291 analysis, where all four proteins changed direction of effect when adjusting for APOE- $\varepsilon 4$  (Figure 5A, 292 Figure 2D-E).

293 **Overlap with the AD brain and CSF proteome.** To evaluate to what extent our LOAD-associated serum 294 proteins reflect the proteomic profile of AD in relevant tissues, we queried data from recent proteomic studies of AD in cerebrospinal fluid (CSF)<sup>36</sup> and brain<sup>37</sup> which also describe tissue specific co-regulatory 295 296 modules. We observed that of our LOAD-associated serum proteins, 51 proteins were also associated 297 with AD in brain as measured by mass-spectrometry, with 32 (63%) being directionally consistent (Figure 298 6A-B) (Supplementary Tables 19-20). Higher directional consistency was observed within the APOE-299 independent protein group, or 15 (71%) of 21 proteins associated with AD in brain tissue. Additionally, 300 60 proteins were directly associated with AD in CSF as measured with SOMAscan (7k) (Figure 6A) with 46 (77%) being directionally consistent (Figure 6B)<sup>21</sup>. The proportion of directionally consistent associations 301 302 between serum and CSF was higher in both the APOE-independent and dependent protein groups, or 303 88% (22 of 25 and 7 of 8 for APOE-independent and dependent proteins, respectively) (Figure 6B, 304 Supplementary Table 19). However, directional inconsistency between plasma and CSF AD proteomic profiles has been reported before in a similar comparison<sup>38</sup>. Fourteen proteins overlapped between all 305 306 three tissues in the context of AD (Figure 6A) (Supplementary Table 19). Many of these proteins have 307 established links or are highly relevant to LOAD, such as Spondin 1 (SPON1), involved in the processing of

amyloid precursor protein (APP)<sup>39</sup>; Secreted Modular Calcium-Binding Protein 1 (SMOC1) previously
 proposed as a biomarker of LOAD in postmortem brains and CSF<sup>40</sup>; Netrin-1 (NTN1), an interactor of APP
 and regulator of amyloid-beta production<sup>41</sup>; Neurofilament light (NEFL), previously proposed as a
 plasma biomarker for LOAD and axon injury<sup>42,43</sup> and Von Willebrand factor (VWF), known for its role in
 blood clotting and associations with LOAD<sup>44</sup> (Supplementary Table 19). Notably, some of the *APOE* dependent proteins were associated with AD across all three tissues such as TBCA and TP53I11.

314 We have previously described the co-regulatory structure of the serum proteome, which can broadly be defined as 27 modules of correlated proteins<sup>26</sup> (Supplementary Table 21). In the current study 315 316 we found that among the 346 aptamers (329 proteins) associated with LOAD (prevalent or incident, any 317 model), five serum protein modules (M27, M3, M11, M2 and M24) were overrepresented (Figure 6C, 318 Supplementary Table 22). In particular, the 140 APOE-independent aptamers were specifically 319 overrepresented in module M27, enriched for proteins involved in neuron development and the 320 extracellular matrix, and module M3 that is associated with growth factor signaling pathways 321 (Supplementary Table 22). By contrast, the 17 APOE-dependent proteins were specifically enriched in protein module M11 (Supplementary Table 22), which is strongly enriched for lipid pathways and is 322 under strong genetic control of the APOE locus<sup>26</sup>. Serum modules M27, M24 and M11 were all enriched 323 324 for AD-associations in CSF (Figure 6C). We next sought to understand to what extent our LOAD-325 associated proteins identified in serum might reflect AD protein signatures in CSF and brain tissue. 326 Among the LOAD-associated proteins measured in serum, we found the APOE-dependent and APOE-327 independent proteins to be enriched in different CSF modules, most of which were also linked to AD 328 (Figure 6D, Supplementary Table 22). In brain tissue, the serum APOE-independent LOAD proteins were 329 particularly enriched in brain module M42 (Matrisome), which is enriched for extracellular matrix (ECM) proteins<sup>37</sup>. Strikingly, M42 was strongly enriched for the AD-proteomic profiles of all three tissues (Figure 330 331 6E, Supplementary Table 22). Interestingly, members of this module (SMOC1, APP, SPON1, NTN1, 332 GPNMB) showed some of the strongest associations in serum to incident LOAD in our study (Figure 2D, 333 Supplementary Table 2) as well as in brain (Figure 6B, Supplementary Table 22). This module has 334 furthermore been demonstrated to be correlated with amyloid beta (A $\beta$ ) deposition in the brain and 335 some of its protein constituents (e.g MDK, NTN1 and SMOC1) have been shown to colocalize with and bind to AB<sup>37</sup>. Additionally, the APOE locus regulates M42 levels in the brain (mod-qTL), and while the 336 337 APOE protein is a member of module M42, this regulation was found to not be solely driven through the levels of the APOE protein itself<sup>37</sup>. Our results simultaneously show that other members of the module, 338 such as SPON1 and SMOC1, exhibit an APOE-independent association to incident LOAD in serum. 339

Interestingly, these same two proteins are increased in CSF thirty years prior to symptom onset in
 autosomal dominant early onset AD<sup>45</sup>. In summary, we demonstrate significant overlaps in LOAD associated protein expression across blood, CSF and brain on both an individual protein level and on
 protein module level.

#### 344 Discussion

345 We describe a comprehensive mapping of the serum protein profile of LOAD that provides insight into 346 processes that are independent or dependent on the genetic control of APOE-E4 (Figure 7). We 347 identified 329 proteins in total that differed in the incident or prevalent LOAD cases compared to non-348 LOAD participants in a population-based cohort with long-term follow-up. Among these, we identified a 349 novel grouping of proteins based on their primary LOAD-association being statistically independent of 350 (130 proteins), or dependent on (17 proteins) APOE-E4 carrier status. Many of the APOE-independent 351 proteins are implicated in neuronal pathways and are shared with the LOAD-associated CSF and brain 352 proteome. The 17 APOE-dependent proteins overlap with AD-associated protein modules in CSF and 353 interact directly with protein partners involved in LOAD, including APP. Another key finding is, amongst 354 these 17 proteins, four proteins change LOAD-associated direction of effect both observationally and 355 genetically when taking APOE- $\varepsilon$ 4 carrier status into account. Collectively, our results suggest that while 356 their primary association with LOAD reflects the risk conferred by APOE- $\varepsilon 4$ , there exists a secondary 357 causal effect of LOAD itself on the protein levels in the reverse direction as supported by the MR 358 analysis, possibly reflecting a response to the disease onset.

359 Previous studies identifying proteins associated with LOAD have been limited to a cross-sectional cohort or are based on all-cause dementia<sup>18,46–48</sup>. Here we extend those findings by distinguishing LOAD 360 361 cases from other types of dementia in a prospective cohort study to identify LOAD-specific serum protein 362 signatures preceding clinical onset. Furthermore, our comparative approach of statistical models with 363 and without APOE-E4 adjustment provides a novel compartmentalized view of the LOAD serum protein 364 profile and demonstrates how protein effects can differ depending on genetic confounders which are 365 imperative to take into consideration. We found that the proteins associated with incident LOAD in our 366 study, in particular those independently of APOE-E4 such as GPNMB, NTN1, SMOC1 and SPON1, overlap with the proteomic profile of LOAD in CSF<sup>38</sup> and brain<sup>37</sup>, and are enriched for neuronal pathways, which 367 368 may reflect an altered abundance of neuronal proteins in the circulation during the prodromal stage of 369 LOAD. These overlaps that we find across independent cohorts and different proteomics technologies 370 suggest that the serum levels of some proteins have a direct link to the biological systems involved in

LOAD pathogenesis and may even provide a peripheral readout of neurodegenerative processes prior to
 clinical diagnosis of LOAD. In particular, the proteins that show directionally consistent effect sizes
 suggest exceptional AD-specific robustness as the measurements vary by tissue, methodology and
 populations.

375 We identified 17 proteins with a particularly strong APOE-dependent association to incident LOAD, of which eight were also associated with prevalent AD in CSF. The association between APOE- $\varepsilon 4$  and 376 circulating levels of these proteins has been reported by our group<sup>24,26,27</sup> and others<sup>49</sup>, but their direct 377 association with incident LOAD has to our knowledge not been previously described. These APOE-378 379 dependent proteins may point directly to the processes through which APOE-E4 mediates its risk on 380 LOAD and provide a readout of the pathogenic process in the circulation of the approximately 50% of LOAD patients worldwide carrying the variant<sup>21,22</sup>. While our data does not provide information on the 381 tissue-origin of the APOE-dependent proteins, nine either exhibit brain-specific gene expression, cluster 382 with brain-specific genes<sup>50</sup> or have been associated with LOAD at the transcriptomic or protein level in 383 brain tissue or CSF (Table 2). At the genetic level, a lookup in the GWAS catalog<sup>51</sup> shows that an intron 384 variant in the *IRF6* gene has a suggestive GWAS association with LOAD via APOE- $\varepsilon$ 4 carrier status 385 interaction<sup>52</sup>. In addition, variants in the *TMCC3* gene have been linked to educational attainment<sup>53</sup> and 386 caudate volume change rate<sup>54</sup> and variants in the *TBCA* gene have been suggestively associated with 387 reaction time<sup>55</sup> and PHF-tau levels<sup>56</sup>. Collectively, the gene expression patterns for these proteins in the 388 389 brain, interactions with proteins involved in neuronal processes and suggestive associations between 390 genetic markers in or near these genes and brain-related outcomes suggest that these APOE-dependent 391 proteins may reflect brain-specific processes affected by APOE-E4 carrier status that affect the risk of 392 developing LOAD. Importantly, the association patterns for ARL2, S100A13 and TBCA suggest the 393 presence of a pathway that is downregulated by APOE- $\varepsilon 4$  early in life, given the consistent effect of 394 APOE- $\varepsilon 4$  on the same proteins in younger cohorts, but upregulated at the onset of LOAD, as supported 395 by the larger observed effects in the APOE- $\varepsilon 4$  adjusted analysis in the ACE cohort of individuals who are 396 closer to diagnosis on the AD trajectory than those in AGES. Additional studies are required to expand on 397 these interpretations and dissect the complex mechanisms at play and to determine if the modulation of 398 the process represented by these proteins has therapeutic potential.

Two proteins, IBSP and APP, were identified to potentially have a causal role in LOAD. IBSP was
 previously associated with plasma amyloid-β and incident dementia<sup>57</sup>, while APP is the precursor protein
 for amyloid-β<sup>58</sup>. Based on the MR analysis for the LOAD-associated proteins that could be tested, the

majority do not appear to be causal in and of themselves but their association with incident LOAD may
still reflect changes that occur years before the onset of LOAD that could be of interest to target before
irreversible damage accumulates.

405 A major strength of this study is the high-quality data from a prospective longitudinal population-406 based cohort study with detailed follow-up, broad coverage of circulating proteins and a comprehensive 407 comparison to the AD-proteome in CSF and brain. The limitations of our study include that our results 408 are based on a Northern European cohort and cannot necessarily be transferred directly to other 409 populations or ethnicities. Additionally, while we partly replicate our overall findings in an external 410 cohort, a greater replication proportion could be anticipated in a more comparable cohort. The ACE 411 cohort consists of clinically referred individuals with MCI and proteomic measurements performed on a 412 different version of the SOMAscan platform. Additionally, different normalization procedures were 413 applied by SomaLogic for the two SOMAscan versions, which may have an effect on the LOAD 414 associations<sup>48</sup>. Further studies are required to determine the impact of time to event, platform and 415 normalization approaches on the associations between circulating proteins and LOAD. Regardless of 416 these differences, we did replicate the majority of the APOE-dependent LOAD associations, including the 417 APOE-dependent change in effect for ARL2, S100A13 and TBCA. We could not test all LOAD-associated 418 proteins for causality, including most of the APOE-dependent proteins, due to lack of significant cis-419 pQTLs for two thirds of the proteins, thus we cannot exclude the possibility that some could be causal 420 but missed by our analysis. Finally, despite our LOAD diagnosis criteria it is possible that some of our 421 findings reflect processes related to dementia in general. As a result, it is critical that these findings be 422 validated in individuals with established amyloid-beta and tau deposits, as well as in experimental 423 settings.

The proteins highlighted in this study and the mechanisms they point to may be used as a source of biomarkers or therapeutic targets that can be modulated for the prevention or treatment of LOAD. This large prospective cohort study, using both a longitudinal and cross-sectional design, represents a unified and comprehensive reference analysis with which past and future serum protein biomarkers and drug targets can be considered, compared, and evaluated.

429

## 430 Acknowledgements

431 The authors acknowledge the contribution of the Icelandic Heart Association (IHA) staff to AGES-432 Reykjavik, as well as the involvement of all study participants. The protein measurements in AGES were 433 supported by Novartis Biomedical Research. The National Institute on Aging (NIA) contracts N01-AG-434 12100 and HHSN271201200022C for V.G. financed the study. IHA received a grant from Althingi (the 435 Icelandic Parliament), V.G. received funding from the NIA (1R01AG065596-01A1) and E.J. from the NIA 436 (1K08AG068604). A.I.L was also funded from the NIA (P30AG066511 and U01AG061357). The content is 437 solely the responsibility of the authors and does not necessarily represent the official views of the 438 National Institutes of Health. The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and 439 440 CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics 441 Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center 442 Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne 443 and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, 444 Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and 445 PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan 446 and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional 447 (FEDER "Una manera de hacer Europa") grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, 448 PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by 449 the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants 450 CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European 451 Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); 452 from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; 453 from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and 454 Janssen, DESCARTES project is funded by German Research Foundation (DFG). Amanda Cano received 455 support from the ISCIII under the grant Sara Borrell (CD22/00125).

#### 456 Author contributions

- 457 Conceptualization E.A.F., Va.G., V.E, Vi.G.
- 458 Formal Analysis E.A.F., Va.G., T.J., A.E.S., E.F.G., A.G., T.A., E.B.D., A.S.
- 459 Resources Vi.G., V.E., A.I.L., A.R., A.P.O., J.J.L., L.L.J., N.T.S., E.C.B.J., L.J.L.
- 460 Data Curation R.P., A.C., M.B., P.G.G., S.V., Va.G., T.A., E.F.G.
- 461 Writing original draft E.A.F., Va.G.

- 462 Writing review & editing All authors
- 463 Visualization E.A.F., Va.G.
- 464 Supervision Va.G., Vi.G.
- 465 Funding Acquisition Vi.G., L.J.L.

#### 466 **Declaration of interests**

L.L.J., A.P.O and J.J.L are employees and stockholders of Novartis. N.T.S and A.I.L are co-founders of
Emtherapro. No other potential conflicts of interest relevant to this article were reported.

### 469 Figure titles and legends

470 Fig. 1 – Study overview Flowchart of the current study. A) Overview of the AGES cohort and study 471 participants. Prevalent non-AD dementia cases were excluded from the analysis. B) Overview of the 472 aptamers tested and their associations with LOAD. Serum measurements of 4782 aptamers were 473 associated to prevalent and incident LOAD status, using logistic and Cox proportional hazards regression 474 models, respectively. From the proteins associated with incident LOAD, sets of 140 proteins with an 475 APOE-independent associations and 17 proteins with an APOE-dependent association were defined. The 476 APOE-dependent proteins were further expanded to first degree protein-protein interaction (PPI) 477 partners. All sets of proteins were subjected to functional enrichment analysis and bi-directional 478 Mendelian Randomization (MR) analysis. C) Overview of the replication cohorts used in the study which 479 include proteins measured in the circulation (ACE) as well as in brain and CSF (Emory). 480 Fig. 2 – Proteins associated with LOAD in AGES. A-B) Volcano plots showing the protein association 481 profile for incident LOAD A) without APOE-E4 adjustment (model 1) and B) with APOE-E4 adjustment 482 (model 2). C) Venn diagram for the overlap between models 1 and 2 for incident LOAD. D-E) Enrichment 483 of top Gene Ontology terms from GSEA analysis for incident LOAD (model 1) shown as **D)** dotplot, 484 stratified by ontology and E) gene-concept network. F-G) Comparison of effect sizes (HR) for incident

- 485 LOAD between the AGES and the ACE cohorts for all proteins reaching nominal significance (P < 0.05) in
- 486 ACE for **F)** model 1 and **G)** model 2.

Fig. 3 – Proteins with APOE-ε4 dependent association to incident LOAD. A) Spaghetti plot showing the
statistical significance of protein associations with incident LOAD across the three models, highlighting a
set of 17 unique proteins (green) whose association with incident LOAD is attenuated upon APOE-ε4
adjustment. The horizontal lines indicate FDR < 0.05 (dashed) and P < 0.05 (dot-dashed). B) Pairwise</li>

Pearson's correlation between the 17 APOE-dependent proteins. C) Forest plot showing the linear
associations between APOE genotype and the 17 APOE-dependent proteins. The beta coefficient shows
the change in protein levels per ε4 allele count. D-E) Forest plots showing the associations between the
17 APOE-dependent proteins and incident LOAD D) without APOE-ε4 adjustment (model 1) and E) with
APOE-ε4 adjustment (model 2). LOAD-HR indicates risk per SD increase of protein levels. Proteins that
change direction of effect between the two models are highlighted in red.

Fig. 4 – Functional enrichment analysis of APOE-dependent protein-protein interaction partners. A) A
scheme of the PPI partners selection, where first degree partners of the APOE-dependent proteins were
extracted from the InWeb database. B-C) Enrichment of selected Gene Ontology terms for the PPI
partner proteins shown as B) dotplot and C) gene-concept network. D-E) Enrichment of top seven unique
Wikipathways shown as D) dotplot and E) gene-concept network.

502 Fig. 5 - Reverse Mendelian randomization analysis. A) Comparison of hazard ratios for incident LOAD 503 with and without APOE-E4 adjustment in the observational analysis, the effects of APOE-E4 on protein 504 levels and reverse MR odds ratios (excluding the APOE locus) for the four APOE-dependent proteins that 505 change direction of effect in both observational and causal analyses when APOE is accounted for. **B-C**) 506 Visual summaries of the observed data. B) Mediation diagrams showing 3 possible hypotheses that could 507 explain the relationship between APOE- $\varepsilon 4$ , LOAD and the four proteins shown in **A**). Our analyses do not 508 support the hypothesis that LOAD mediates the effect of APOE-E4 on proteins (Hypothesis 1) nor the 509 other way around (Hypothesis 2). However, our results from both the observational and causal analyses 510 support the hypothesis that two mechanisms are at play that affect the same proteins in the opposite 511 direction (Hypothesis 3). C) The APOE-E4 mutation leads to increased risk of LOAD via its effects in brain 512 tissue. The same mutation results in a downregulation of serum levels of four proteins that are 513 themselves negatively associated with incident LOAD. Additionally, other non-APOE LOAD risk variants 514 lead to upregulation of the same proteins in the reverse MR analysis, possibly reflecting a response to 515 LOAD or its genetic liability.

Fig. 6 – Overlap between AD protein signatures in serum, brain and CSF. A) A Venn diagram showing
the overlap of AD-associated proteins in serum, brain and CSF. B) A comparison of the effect sizes for AD
associated proteins that overlap between serum and brain (top) and serum and CSF (bottom). The
proteins are stratified based on the APOE-dependence in AGES for incident LOAD. The effect size in AGES
is shown for incident LOAD model 1, except for proteins that were uniquely identified using the shorter
10-year follow-up or prevalent LOAD, in which case the respective effect size from the significant

- 522 association is shown. C-E) Heatmap showing the enrichment of AD-associated proteins by tissue type (x-
- 523 axis) in **C)** the AGES serum protein modules, **D)** Emory CSF protein modules and **E)** Emory brain protein
- 524 modules (y-axis).
- 525 Fig. 7 Graphical summary of the results.

## 526 Tables with titles and legends

- 527 **Table 1 –** A summary table of the top 20 significant *APOE-independent* proteins associated with incident
- 528 LOAD in AGES. The effect size (Hazard Ratio (Confidence Interval)) and level of significance (P, FDR) is
- 529 shown for model 2, adjusting for age, sex and *APOE*-ε4. The final column indicates if the aptamers have
- 530 been orthogonally validated by mass-spectrometry<sup>26</sup>. The *APOE*-independency is defined as proteins
- remaining significantly (FDR < 0.05) associated with incident LOAD after APOE- $\varepsilon 4$  adjustment.

Entrez symbol	HR	Р	FDR	MS validated
CD4	0.79 (0.73-0.87)	1.9E-07	9.3E-04	
BRD4	0.82 (0.75-0.89)	1.4E-06	3.4E-03	
SPON1	1.24 (1.13-1.36)	3.6E-06	3.9E-03	
CLEC2L	0.83 (0.77-0.9)	5.7E-06	3.9E-03	
SOD3	1.21 (1.11-1.31)	5.2E-06	3.9E-03	Yes
ACHE	1.22 (1.12-1.33)	3.9E-06	3.9E-03	
IL1R1	1.23 (1.12-1.34)	4.7E-06	3.9E-03	
ADAM30	0.83 (0.77-0.9)	1.1E-05	6.0E-03	
PLA2G2E	0.82 (0.75-0.89)	1.2E-05	6.0E-03	
TFPI	1.2 (1.11-1.31)	1.3E-05	6.0E-03	Yes
SVEP1	1.21 (1.11-1.33)	2.5 E-05	0.011	Yes
SVEP1	1.21 (1.11-1.32)	3.3E-05	0.011	Yes
LCORL	0.82 (0.75-0.9)	3.2E-05	0.011	
PROK1	0.84 (0.77-0.91)	3.1E-05	0.011	
NCAM1	1.2 (1.1-1.3)	4.0E-05	0.011	Yes
SMOC1	1.21 (1.11-1.33)	3.9E-05	0.011	
SOD3	1.19 (1.09-1.29)	4.0E-05	0.011	
NLGN1	1.18 (1.09-1.28)	4.5 E-05	0.011	
SURF1	1.19 (1.1-1.3)	4.3E-05	0.011	
IGF2	0.84 (0.77-0.92)	5.4E-05	0.012	

532

Table 2 – A summary table of the 17 APOE-dependent LOAD associated proteins, describing their tissue
 specificity in the Human Protein Atlas v22, results from the association analyses in AGES, references for
 previous associations with APOE or LOAD and whether the aptamers have been orthogonally validated

## via MS<sup>26</sup>. The APOE-dependency is defined as being significant (FDR<0.05) in model 1 and fully non-

## significant in model 2 (P>0.05) for incident LOAD.

					Incident LOAD (Cox)				APOE-e4 (linear regression)				
					Мо	del 1	Мос	lei 2					
Entrez Symbol	Tissue specificity	Tiss ue cluster	LOAD ref	APOE ref	HR	FDR	HR	Р	Beta	SE	Р	FDR	MS validation
LRRN1	Brain	Brain	59	49	1.258	1.E-05	1.018	0.711	1.061	0.023	<1E-300	<1E-300	
S100A13	Low	Mitochondria		49	0.799	7.E-05	1.099	0.092	-1.090	0.021	<1E-300	<1E-300	
ТВСА	Low	Vesicular transport		49	0.782	7.E-06	1.086	0.145	-1.183	0.020	<1E-300	<1E-300	Yes
CTF1	Low	Fibroblasts, ECM	60	49	1.262	2.E-04	1.077	0.147	0.611	0.021	1.E-171	5.E-171	
ARL2	Low	Striated muscle			0.835	0.002	1.093	0.077	-0.991	0.022	<1E-300	<1E-300	
C1 orf 56	Testis	Spermatogenesis			1.200	0.002	1.070	0.113	0.513	0.026	6.E-85	9.E-85	
MSN Low		Neutrophils, Inflammatory response	61		1.186	0.003	1.039	0.388	0.608	0.025	9.E-122	2.E-121	
TMCC3	Brain	Brain, Nervous system development	62		0.849	0.005	0.962	0.364	-0.517	0.026	4.E-86	7.E-86	
HBQ1	Bone marrow	Neutrophils, Humoral immune response			0.860	0.013	0.966	0.423	-0.455	0.025	1.E-69	1.E-69	
IRF6 Esophagus, Skin		Squamous epithelial cells			0.876	0.032	1.033	0.458	-0.675	0.025	4.E-153	1.E-152	
IFIT2	IFIT2 Bone marrow				0.875	0.035	0.949	0.214	-0.275	0.026	2.E-26	2.E-26	
TP53I11	Low	Adipose tissue, ECM organization			0.879	0.036	0.981	0.653	-0.436	0.026	1.E-60	1.E-60	
FAM159B	Brain and other	Unknown function			0.882	0.039	0.977	0.591	-0.419	0.026	8.E-56	9.E-56	
NDE1	Low	Brain, Nervous system development	63		0.876	0.039	1.001	0.985	-0.489	0.025	3.E-80	5.E-80	Yes
NEFL	Brain	Brain, Neuronal signaling	64		0.878	0.041	1.031	0.516	-0.578	0.024	2.E-121	4.E-121	
GSTM1	Brain	Liver, Metabolism	65	66	1.136	0.042	1.077	0.087	0.276	0.026	1.E-26	1.E-26	
GGT2	Kidney, Thyroid	Kidney, Transmembrane transport			0.887	0.048	0.981	0.646	-0.384	0.026	2.E-47	3.E-47	

- 539 **Table 3** Replication of the LOAD associated proteins from AGES in the ACE cohort. All proteins with
- nominal P<0.05 in either model are shown. P and FDR values <0.05 are highlighted in bold.

Table 3	Table 3									
	Model 1 Model 2									
Aptamer	Gene symbol	APOE proteins AGES	HR	95% CI	Р	FDR	HR	95% CI	Р	FDR
11293_14_3	LRRN1	Dependent	1.410	1.256-1.582	5.4E-09	1.8E-06	1.142	0.969-1.346	0.112	0.839
5744_12_3	C1 orf 56	Dependent	1.354	1.190-1.541	4.3E-06	5.2E-04	1.175	1.022-1.352	0.024	0.565
13732_79_3	CTF1	Dependent	1.324	1.174-1.494	4.7E-06	5.2E-04	1.034	0.888-1.205	0.666	0.958
10082_251_3	NEFL	Dependent	0.771	0.683-0.870	2.5E-05	0.002	1.084	0.917-1.282	0.346	0.958
12501_10_3	TBCA	Dependent	0.789	0.695-0.895	2.3E-04	0.015	1.279	1.063-1.538	0.009	0.336
6462_12_3	TIMP4	Independent	1.261	1.109-1.434	4.0E-04	0.022	1.236	1.087-1.405	1.2E-03	0.198
8819_3_3	IGFBP2	Independent	1.253	1.087-1.445	0.002	0.085	1.250	1.082-1.443	0.002	0.204

r			1							1
2570_72_5	IGFBP2	Independent	1.237	1.080-1.415	0.002	0.085	1.234	1.077-1.414	0.002	0.204
8469_41_3	IGFBP2	Independent	1.230	1.066-1.418	0.004	0.164	1.222	1.059-1.410	0.006	0.316
10978_39_3	GH2	Independent	1.182	1.043-1.340	0.009	0.298	1.131	0.998-1.281	0.053	0.751
2813_11_2	AGRP	Other	1.187	1.039-1.355	0.011	0.346	1.196	1.048-1.364	0.008	0.323
7100_31_3	CD2	Independent	1.166	1.031-1.317	0.014	0.353	1.102	0.975-1.246	0.121	0.839
6168_11_3	TP53	Other	1.190	1.034-1.369	0.015	0.353	1.127	0.976-1.302	0.104	0.839
4964_67_1	ERAP1	Independent	0.861	0.763-0.972	0.015	0.353	0.841	0.742-0.953	0.007	0.316
7223_60_3	S100A13	Dependent	0.853	0.749-0.971	0.016	0.353	1.500	1.240-1.816	3.1E-05	0.010
4930_21_1	STC1	Independent	1.173	1.024-1.343	0.021	0.391	1.174	1.024-1.346	0.021	0.565
9539_25_3	COL26A1	Other	0.865	0.764-0.979	0.022	0.391	0.890	0.788-1.005	0.059	0.756
7239_9_3	GSTM1	Dependent	1.159	1.021-1.316	0.023	0.391	1.070	0.941-1.217	0.304	0.951
4929_55_1	SHBG	Other	1.168	1.022-1.335	0.023	0.391	1.149	1.005-1.313	0.042	0.751
13118_5_3	SMOC1	Independent	1.172	1.022-1.345	0.024	0.391	1.157	1.006-1.331	0.041	0.751
5660_51_3	SOD3	Independent	1.162	1.018-1.326	0.026	0.411	1.162	1.018-1.325	0.026	0.565
5581_28_3	FGL1	Other	1.149	1.015-1.301	0.028	0.430	1.118	0.988-1.266	0.077	0.757
1 30 22 _ 20 _ 3	TP53 11	Dependent	0.877	0.777-0.991	0.035	0.458	1.059	0.930-1.206	0.388	0.958
8235_48_3	CHGB	Other	1.151	1.010-1.311	0.035	0.458	1.123	0.983-1.282	0.088	0.797
7016_12_3	GCNT1	Independent	0.864	0.754-0.990	0.036	0.458	0.874	0.763-1.001	0.052	0.751
13731_14_3	C7	Independent	1.159	1.010-1.331	0.036	0.458	1.147	1.001-1.316	0.049	0.751
2925_9_1	SERPINE1	Other	0.875	0.770-0.995	0.042	0.511	0.870	0.762-0.992	0.038	0.751
3290_50_2	CD109	Independent	0.884	0.784-0.996	0.043	0.511	0.896	0.794-1.012	0.076	0.757
6626_81_3	CHST12	Independent	0.871	0.761-0.997	0.045	0.518	0.904	0.790-1.036	0.146	0.848
6604_59_3	NDNF	Other	0.879	0.774-0.999	0.048	0.528	0.897	0.790-1.019	0.096	0.817
14129_1_3	IFNA7	Other	1.131	1.000-1.279	0.051	0.543	1.134	1.003-1.282	0.045	0.751
8072_19_3	MZT1	Independent	1.118	0.996-1.256	0.058	0.604	1.146	1.020-1.287	0.022	0.565
4982_54_1	P13	Other	1.139	0.989-1.311	0.070	0.608	1.185	1.027-1.366	0.020	0.565
4297_62_3	SPON1	Independent	1.127	0.989-1.285	0.073	0.608	1.167	1.019-1.336	0.025	0.565
8242_9_3	CLEC2L	Independent	1.102	0.974-1.248	0.124	0.686	1.136	1.003-1.287	0.045	0.751
12587_65_3	ARL2	Dependent	0.909	0.804-1.028	0.130	0.686	1.252	1.075-1.457	0.004	0.255

541

#### 543 Methods

### 544 AGES study population

545 Participants aged 66 through 96 were from the Age, Gene/Environment Susceptibility (AGES)-Reykjavik 546 Study cohort. AGES is a single-center prospective population-based study of deeply phenotyped subjects 547 (n = 5,764, mean age 76.62±25.6 years) and survivors of the 40-year-long prospective Reykjavik study, an 548 epidemiologic study aimed to understand aging in the context of gene/environment interaction by 549 focusing on four biologic systems: vascular, neurocognitive (including sensory), musculoskeletal, and body composition/metabolism<sup>30</sup>. Of the AGES participants, 3,411 attended a 5-year follow-up visit. LOAD 550 551 diagnosis at AGES baseline and follow-up visits was carried out using a three-step procedure described in Sigurdsson et al.<sup>67</sup>. Cognitive assessment was carried out on all participants. Neuropsychological testing 552 553 was performed on individuals with suspected dementia. Individuals remaining suspect for dementia 554 underwent further neurologic and proxy examinations in the second diagnosis step. Thirdly, a panel 555 comprising of a neurologist, geriatrician, neuroradiologist, and neuropsychologist assessed the positive scoring participants according to international guidelines<sup>30</sup> and gave a dementia diagnosis. The 556 557 participants were followed up for incident dementia through medical and nursing home reports and 558 death certificates. The follow-up time was up to 16.9 years, with the last individual being diagnosed 16 559 years from baseline. Nursing home reports were based on intake exams upon entry or standardized procedures carried out in all Icelandic nursing homes<sup>68</sup>. The participants diagnosed at baseline were 560 561 defined as prevalent LOAD cases while individuals diagnosed with LOAD during the follow-up period 562 were defined as incident LOAD cases. All prevalent non-AD dementia cases (n=163) were excluded from 563 analyses.

564 Age, sex, education, and lifestyle variables were assessed via questionnaires at baseline. 565 Education was categorized as primary, secondary, college, or university degree. Smoking was 566 characterized as current, former, or never smoker. APOE genotyping was assessed via microplate array diagonal gel electrophoresis (MADGE)<sup>69</sup>. BMI and hypertension were assessed at baseline. BMI was 567 568 calculated as weight (kg) divided by height (m) squared, and hypertension was defined as 569 antihypertensive treatment or BP >140/90 mm Hg. Type 2 diabetes was defined from self-reported 570 diabetes, diabetes medication use, or fasting plasma glucose ≥7 mmol/L. Serum creatinine was measured 571 via the Roche Hitachi 912 instrument and estimated glomerular filtration rate (eGFR) derived with the four-variable MDRD study equation<sup>70</sup>. The AGES study was approved by the NBC in Iceland (approval 572

number VSN-00-063), and by the National Institute on Aging Intramural Institutional Review Board, and
the Data Protection Authority in Iceland.

#### 575 Proteomic measurements

The proteomic measurements in AGES have been described in detail elsewhere<sup>27,71</sup> and was available for 576 577 5,457 participants. Briefly, a custom version of the SOMAscan platform (Novartis V3-5K) was applied based on the slow-off rate modified aptamer (SOMAmer) protein profiling technology<sup>72,73</sup> including 4.782 578 aptamers that bind to 4,137 human proteins. Serum was prepared using a standardized protocol<sup>74</sup> from 579 580 blood samples were collected after an overnight fast, stored in 0.52ml aliquots at -80°C and serum 581 samples that had not been previously thawed were used for the protein measurements. All samples 582 were run as a single set at SomaLogic Inc. (Boulder, CO, US). Hybridization controls were used to adjust 583 for systematic variability in detection and calibrator samples of three dilution sets (40%, 1%, and 0.005%) 584 were included so that the degree of fluorescence was a quantitative reflection of protein concentration. 585 All aptamers that passed quality control had median intra-assay and inter-assay coefficient of variation 586 (CV)2<25%. Finally, intraplate median signal normalization was applied to individual samples by 587 SomaLogic instead of normalization to an external reference of healthy individuals, as is done for later 588 versions of the SOMAscan platform (https://somalogic.com/wp-

589 content/uploads/2022/07/SL00000048\_Rev-3\_2022-01\_-Data-Standardization-and-File-Specification-

590 Technical-Note-v2.pdf).

591 ACE cohort

592 ACE Alzheimer Center Barcelona was founded in 1995 and has collected and analyzed roughly 18,000 593 genetic samples, diagnosed over 8,000 patients, and participated in nearly 150 clinical trials to date. For 594 more details, visit www.fundacioace.com/en. The syndromic diagnosis of all subjects of the ACE cohort 595 was established by a multidisciplinary group of neurologists, neuropsychologists, and social workers. 596 Healthy controls (HCs), including individuals with subjective cognitive decline (SCD) diagnosis, were 597 assigned a Clinical Dementia Rating (CDR) of 0, and mild cognitive impairment (MCI) individuals a CDR of 0.5. For MCI diagnoses, the classification of López et al., 2003, and Petersen's criteria were used<sup>75–78</sup>. The 598 599 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) guidelines were used for AD diagnosis<sup>79</sup>. All ACE clinical protocols have been previously published<sup>80–82</sup>. Paired plasma and CSF 600 samples<sup>83</sup>, following consensus recommendations, were stored at -80°C. A subset of ACE cohort was 601 analyzed with the SOMAscan 7k proteomic platform<sup>84</sup> (n = 1,370), (SomaLogic Inc., Boulder, CO, US). The 602

proteomic data underwent standard quality control procedures at SomaLogic and was median
normalized to reference using the Normalization by Maximum Likelihood (ANML) method
(https://somalogic.com/wp-content/uploads/2022/07/SL00000048\_Rev-3\_2022-01\_-DataStandardization-and-File-Specification-Technical-Note-v2.pdf). Additionally, *APOE* genotyping was
assessed using TaqMan genotyping assays for rs429358 and rs7412 SNPs (Thermo Fisher). Genotypes
were furthermore extracted from the Axiom 815K Spanish Biobank Array (Thermo Fisher) performed by
the Spanish National Center for Genotyping (CeGen, Santiago de Compostela, Spain).

#### 610 *Statistical analysis*

611 Protein measurement data was centered, scaled and Box-Cox transformed, and extreme outliers excluded as previously described<sup>71</sup>. Sample size was not predetermined by any statistical method but 612 613 rather by available data. The associations of serum protein profiles with prevalent AD (n = 167) were 614 examined cross-sectionally via logistic regression at baseline. The associations of serum protein profiles 615 with incident LOAD (n = 655) were examined longitudinally via Cox proportional-hazards models. 616 Participants who died or were diagnosed with incident non-AD dementia were censored at date of death 617 or diagnosis. To account for hazard ratio variability which may arise with lengthy follow-ups, a secondary 618 analysis using 10-year follow-up cut-off of incident LOAD was performed ( $n_{LOAD}$  = 432). To compare the 619 fits of the two follow-up times and test for time-dependence of the coefficients we used anova and the survsplit function from the Survival R package<sup>85</sup>. For both prevalent and incident LOAD, we examined 620 three covariate-adjusted models. The primary model (model 1) included the covariates sex and age. 621 622 Model 2 included as an additional covariate the APOE- $\varepsilon 4$  allele count. The third model (model 3) 623 included additional adjustment for cardiovascular risk factors, lifestyle, and kidney function (BMI, type 2 624 diabetes, education, hypertension, smoking history, eGFR) as they have been associated with risk of 625 LOAD<sup>86</sup>. Benjamini-Hochberg false discovery rate (FDR) was used to account for multiple hypothesis 626 testing. Analyses were conducted using R version 4.2.1. ACE SomaLogic proteomics data was similarly 627 Box-Cox transformed and association analysis performed in the same manner as in AGES.

628 <u>APOE-dependence criteria</u> of the proteins were defined as serum proteins that met FDR significance of < 629 0.05 in association with incident LOAD in model 1, thus unadjusted for the APOE- $\epsilon$ 4 allele, but whose 630 nominal significance was abolished upon APOE- $\epsilon$ 4 correction in model 2 (P > 0.05). Serum proteins that 631 remained nominally significantly associated with incident LOAD (P < 0.05) upon APOE- $\epsilon$ 4 correction but 632 changed direction of effect were also considered to meet the APOE dependence criteria, as a reversal of 633 the effect indicates that the primary association is driven by APOE- $\epsilon$ 4.

634 Functional enrichment analyses were performed using Over-Representation Analysis (ORA) and Gene Set Enrichment Analysis (GSEA) using the R packages ClusterProfiler and fgsea<sup>87,88</sup>. The association 635 636 significance cut-off for inclusion in ORA was FDR < 0.05. Background for both methods was specified as 637 all proteins tested from the analysis leading up to enrichment testing. The investigated gene sets were 638 the following: Gene Ontology, Human Phenotype Ontology, KEGG, Wikipathways, Reactome, Pathway 639 Interaction Database (PID), MicroRNA targets (MIRDB and Legacy), Transcription factor targets (GTRD and Legacy), ImmuneSigDB and the Vaccine response gene set<sup>89</sup>. Finally, we looked into tissue gene 640 expression signatures via the same methods (ORA and GSEA) using data from GTEX<sup>90</sup> and The Human 641 642 Protein Atlas, where gene expression patterns across tissues were categorized in a similar manner as described by Uhlen et al<sup>50</sup> and tissue-elevated expression considered as gene expression in any of the 643 644 categories 'tissue-specific', 'tissue-enriched' or 'group-enriched'. MinGSSize was set at 2 when 645 investigating the LOAD-associated serum proteins directly. When investigating the APOE-dependent 646 protein interaction partners, minGSSize was set to 15 and maxGSSize was set to 500. Overrepresentation 647 of brain cell type markers among LOAD-associated proteins was tested using a Fisher's exact test, with 648 the SOMApanel protein set as background. Tissue specificity lookup for the top LOAD associated proteins was based on the Human Protein Atlas version 22 (https://v22.proteinatlas.org/). For the protein-protein 649 interaction (PPI) network analysis, PPIs from  $InWeb^{32}$  (n = 14,448, after Entrez ID filtering) were used to 650 651 obtain the first-degree interaction partners of the APOE-dependent proteins.

#### 652 Protein comparisons across serum, CSF and brain

653 To compare protein modules and AD associations across tissues, protein modules and protein associations to AD were obtained from brain<sup>37</sup> and CSF<sup>36</sup>. The brain data, from the Banner Sun Health 654 Research Institute<sup>91</sup> and ROSMAP<sup>92</sup>, included TMT-MS-based quantitative proteomics for 106 controls, 655 200 asymptomatic AD cases and 182 AD cases. The CSF samples were collected under the auspices of the 656 Emory Goizueta Alzheimer's Disease Research Center (ADRC) and Emory Healthy Brain Study (EHBS)<sup>36</sup>. 657 658 The cohort consisted of 140 healthy controls and 160 patients with AD as defined by the NIA research framework<sup>93</sup>. Protein measurements were performed using TMT-MS and SomaScan (7k). Only 659 660 SomaLogic protein measurements were included in the comparison between CSF and serum, which were 661 median normalized. Proteins were matched on SomaLogic aptamer ID when possible but otherwise by 662 Entrez gene symbol. Overlaps between modules and AD-associated (FDR<0.05) proteins across tissues 663 were evaluated with Fisher's exact test.

664 Mendelian randomization

665 A two-sample bi-directional Mendelian randomization (MR) analysis was performed to first evaluate the 666 potential causal effects of serum protein levels on AD (forward MR), and second to evaluate the 667 potential causal effects of AD or its genetic liability on serum protein levels (reverse MR). All aptamers 668 significantly (FDR<0.05) associated with LOAD (incident or prevalent) were included in the MR analyses, 669 or a total of 346 unique aptamers (Supplementary Tables 2, 3 and 5), of which 320 aptamers were 670 significant in the full follow-up incident LOAD analysis (models 1-3), 106 aptamers were significant in the 671 10-year follow-up incident LOAD analysis (model 1-3) and ten aptamers were significant in the prevalent LOAD analysis (models 1-3). Genetic instruments for serum protein levels were obtained from a GWAS of 672 serum protein levels in AGES<sup>24</sup> and defined as follows. All variants within a 12Mb (±5002kb) cis-window 673 674 for the protein-encoding gene were obtained for a given aptamer. A cis-window-wide significance level 675 Pb2=20.05/N, where N equals the number of SNPs within a given cis-window, was computed and 676 variants within the cis window for each aptamer were clumped ( $r^2 \square \ge \square 0.2$ ,  $P \square \ge \square P \square$ ). The effect of the 677 genetic instruments for serum protein levels on LOAD risk was obtained from a GWAS on GWAS on 39,106 clinically diagnosed LOAD cases, 46,828 proxy-LOAD and dementia cases and 401,577 controls of 678 European ancestry<sup>19</sup>. Genetic instruments for the serum protein levels not found in the LOAD GWAS data 679 680 set were replaced by proxy SNPs (r<sup>2</sup>2>20.8) when possible, to maximize SNP coverage. Genetic instruments for LOAD in the reverse causation MR analysis were obtained from the same LOAD GWAS<sup>24</sup>, 681 682 where genome-wide significant variants were extracted ( $P \square < \square 5e$ -8) and clumped at a more stringent LD 683 threshold (r22≥20.01) than for the protein instruments to limit overrepresentation of SNPs from any 684 given locus across the genome. In the reverse causation MR analysis, cis variants (±5001kb) for the given 685 protein were excluded from the analysis to avoid including pleiotropic instruments affecting the 686 outcome (protein levels) through other mechanisms than the exposure (LOAD). A secondary reverse 687 causation MR analysis was performed excluding any variants in the APOE locus (chr19:45,048,858-688 45,733,201). Causal estimate for each protein was obtained by the generalized weighted least squares 689 (GWLS) method<sup>94</sup>, which accounts for correlation between instruments. Causality for proteins with single 690 cis-acting variants was assessed with the Wald ratio estimator. For the reverse causation MR analysis, 691 the inverse variance weighted method was applied due to a more stringent LD filtering of the 692 instruments. Instrument heterogeneity was evaluated with Cochran's Q test and horizontal pleiotropy 693 with the MR Egger test.

## 694 Supplemental information titles and legends

695 **Supplementary Figure 1 – A-B)** Volcano plots showing the protein association profile for incident LOAD,

restricted to 10-year follow-up **A**) without APOE e4 adjustment (model 1) and **B**) with APOE e4

adjustment (model 2). C) Venn diagram for the aptamer overlap between models 1 and 2 for incident

698 AD, restricted to 10-year follow-up.

Supplementary Figure 2 – A-B) Volcano plots showing the protein association profile for prevalent LOAD,
A) without APOE e4 adjustment (model 1) and B) with APOE e4 adjustment (model 2). C) Venn diagram

for the aptamer overlap between models 1 and 2 for prevalent LOAD. **D)** Heatmap comparing the effect

sizes for models 1 and 2 and both prevalent (odds ratio) and incident LOAD (hazard ratio). Serum protein

703 module membership and *APOE*-dependence (see Methods for definition) are annotated at the top.

Supplementary Figure 3 – Spaghetti plots showing the statistical significance of protein associations with
 A) prevalent LOAD and B) incident LOAD restricted to 10 year follow-up across the three models,
 highlighting the 17 *APOE*-dependent proteins (green) defined as those whose association with incident
 LOAD is attenuated with *APOE* e4 adjustment for incident AD using full follow-up (Fig 2a).

708 **Supplementary Figure 4 –** Boxplots visualizing protein levels in **A)** AGES serum samples, see

Supplementary Table 9 for statistical evaluation and B) ACE plasma samples, stratified by APOE-e4 allele
 carrier and incident LOAD status, for the 17 proteins with APOE-dependent association to incident LOAD
 in AGES.

Supplementary Figure 5 – A) Histogram showing the incident LOAD HR for APOE-e4 allele count in AGES from Cox proportional hazard regression models adjusted for a single LOAD-associated protein at a time, in addition to age and sex. The dashed line indicates the HR for APOE-e4 when only adjusting for age and sex. The proteins with the largest effect on the APOE-e4 HR when included in the model are denoted. B) Forest plot showing the incident LOAD HR with 95% confidence intervals for APOE-e4 when adjusting for each of the 17 APOE-dependent model in the Cox proportional hazard regression.

Supplementary Figure 6 – A-B) Spaghetti plots showing the statistical significance of protein associations with incident LOAD across three statistical models, adjusting for age and sex, and then additionally either serum A) total cholesterol or B) LDL cholesterol, and finally APOE e4 carrier status. The LOAD association of the 17 APOE-dependent proteins (green) is not attenuated when adjusting for total cholesterol or LDL but only when adjusting for APOE e4 carrier status. C-H) Protein associations with serum total cholesterol (C-E) and LDL cholesterol (F-H). The density plots show the effect size for the associations between cholesterol levels and all measured proteins stratified by their AD association, adjusting for age

and sex (C and F), and additionally *APOE-e4* carrier status (D and G). E) and H) Comparisons of the effect
sizes for association with cholesterol levels in the models with (y-axis) and without (x-axis) *APOE-e4*adjustment shows that the effect size is often increased for the *APOE*-dependent proteins (red) after *APOE-e4* adjustment.

Supplementary Figure 7 – Reverse MR analysis (excluding the APOE locus) for the causal effect of A)
total cholesterol and B) LDL cholesterol on serum levels of the 17 APOE-dependent proteins. C-E) For
each protein, a comparison of the effect sizes for the association with the APOE-ε4 genotype (x-axis) and
C) incident LOAD, D) total cholesterol and E) LDL cholesterol (y-axis). TC, total cholesterol; LDL, low
density lipoprotein cholesterol.

Supplementary Figure 8 – MR scatterplots for all proteins with more than one genetic instrument and
 with P<0.05 in the MR analysis for a causal effect of protein levels on AD. Each point represents a genetic</li>
 instrument (SNP) and shows its effect on serum protein levels (x-axis) and AD (y-axis). The slope of the
 blue line indicates the inverse variance weighted MR effect.

Supplementary Figure 9 – Example MR scatterplots from the reverse MR analysis for a causal effect of
 AD on serum protein levels, showing discordant direction of effect (inverse variance weighted method
 indicated by slope of dashed line) when including (left) or excluding (right) APOE genetic variants. Each
 point represents a genetic instrument (SNP) and shows its effect on AD (x-axis) and serum protein levels
 (y-axis).

Supplementary Figure 10 – A forest plot showing the results for individual SNPs in the reverse MR
analysis for a causal effect of AD on serum protein levels, together with the full multi-SNP IVW estimate
(red). Plots are shown for the five proteins with FDR<0.1 in the primary reverse MR analysis, excluding</li>
variants from the *APOE* locus.

747Supplementary Figure 11 – Comparison of the effects of  $APOE - \varepsilon 4$  (left) versus AD, as evaluated through748reverse MR analysis excluding APOE variants, (right) on serum protein levels in AGES and two additional749cohorts. Results are shown for the four APOE-dependent proteins with opposite direction of effect in750the two analyses. The AGES results are shown for the full cohort and two age strata.

Supplementary Table 1 - Baseline characteristics of the AGES cohort stratified by LOAD status. P values
 are obtained from t-test for continuous variables, and chi-square test for categorical variables. P and FDR
 values <0.05 are highlighted in bold.</li>

754 **Supplementary Table 2 –** Proteins significantly associated with incident LOAD after FDR (Benjamini-

Hochberg) correction are displayed. The full Cox proportional hazards regression model (Model 3) was

- 756 adjusted for baseline age, sex, APOE-e4 genotype, body mass index, diabetes, education, hypertension,
- 757 smoking history, and eGFR as denoted below. P and FDR values <0.05 are highlighted in bold.
- Abbreviations: HR, Hazard ratio; Cl, Confidence Interval, Zph: proportional hazard test statistic. Estimates
- represent difference in LOAD risk per standard deviation increase of aptamer level.
- 760 **Supplementary Table 3** Proteins significantly associated with incident LOAD with 10-year follow-up
- after FDR (Benjamini-Hochberg) correction are displayed. The full Cox proportional hazards regression
- model (Model 3) was adjusted for baseline age, sex, APOE-e4 genotype, body mass index, diabetes,
- reducation, hypertension, smoking history, and eGFR. P and FDR values <0.05 are highlighted in bold.
- Abbreviations: HR, Hazard ratio; Cl, Confidence Interval, Zph: proportional hazard test statistic. Estimates
- represent difference in LOAD risk per standard deviation increase of aptamer level.
- Supplementary Table 4 Comparisons of the Cox models with full follow-up vs 10 year follow up using
   ANOVA. P and FDR values <0.05 are highlighted in bold. Abbreviations: df, degrees of freedom</li>
- 768 Supplementary Table 5 Proteins significantly associated with prevalent LOAD after FDR (Benjamini-
- Hochberg) correction. The full logistic regression model (Model 3) was adjusted for baseline age, sex,
- APOE-e4, body mass index, diabetes, education, hypertension, smoking history, and eGFR. P and FDR
- values <0.05 are highlighted in bold. Abbreviations: OR, odds ratio; SE, standard error. Estimates
- represent difference in LOAD risk per standard deviation increase of aptamer level.
- Supplementary Table 6 Replication of the LOAD associated proteins from Supplementary Table 5 in the
   ACE cohort. Proteins significantly associated with prevalent LOAD after FDR (Benjamini-Hochberg)
- correction are displayed. Logistic regression models were adjusted for baseline age + sex (Model 1) and
- additionally for APOE-e4 in Model 2. P and FDR values <0.05 are highlighted in bold. Abbreviations: OR,
- odds ratio; SE, standard error. Estimates represent difference in LOAD risk per standard deviation
- increase of aptamer level.
- Supplementary Table 7 Results from Gene Set Enrichment Analysis (GSEA) and Overrepresentation
   Analysis (ORA) of the prevalent LOAD associated proteins against protein-coding gene sets labeled below
   using the R packages listed below. P values were adjusted for multiple comparisons using FDR (Benjamini
   Hochberg). Abbreviations: ES, Enrichment score; NES, Enrichment score normalized

Supplementary Table 8 – Gene Set Enrichment Analysis and Overrepresentation Analysis of incident
 LOAD associated proteins in AGES against protein-coding gene sets labeled below using the R packages
 listed below. P values were adjusted for multiple comparisons using FDR (Benjamini Hochberg). P and
 FDR values <0.05 are highlighted in bold. Abbreviations: ES, Enrichment score; NES, Enrichment score</li>
 normalized; size of the pathway after removing missing genes; leadingEdge, vector of genes that drive
 the enrichment.

Supplementary Table 9 – Replication of the incident LOAD associated proteins from Supplementary
Table 2 in the ACE cohort. Proteins significantly associated with incident LOAD after FDR (BenjaminiHochberg) correction are displayed. Linear and Cox proportional regression models were adjusted for
baseline age, sex (Model 1) and additionally for APOE-e4 genotype in Model 2. P and FDR values <0.05</li>
are highlighted in bold. Abbreviations: HR, Hazard ratio; Cl, Confidence Interval, Zph: proportional hazard
test statistic. Estimates represent difference in LOAD risk per standard deviation increase of aptamer
level.

Supplementary Table 10 – First-degree protein partners of the APOE-dependent proteins from the
InWeb database (Li et al. (2016), Nature Methods 2016 14:1 14, 61–64. 10.1038/nmeth.4083).
Abbreviations: CS, confidence score.

Supplementary Table 11 – Gene Set Enrichment Analysis and Overrepresentation Analysis of the first degree protein partners of the APOE-dependent LOAD associated proteins against protein-coding gene
 sets labeled below using the R packages listed below. P values were adjusted for multiple comparisons
 using FDR (Benjamini Hochberg).

Supplementary Table 12 – Forward MR analysis examining the causal effects of the protein partners of
 the AGES-defined APOE-dependent LOAD-associated proteins on AD. P and FDR values <0.05 are</li>
 highlighted in bold. Abbreviations: OR, odds ratio; SE, standard error; eggerPass, passes Egger pleiotropy
 sensitivity analysis; wmPass, passes weighted median sensitivity analysis

Supplementary Table 13 – Reverse MR analysis examining the causal effects of blood cholesterol (total
 and LDL) on the AGES-defined APOE-dependent LOAD-associated proteins. P and FDR values <0.05 are</li>
 highlighted in bold. Abbreviations: OR, odds ratio; SE, standard error.

Supplementary Table 14 – Overview of the genetic instruments and their associations with serum levels
in AGES

Supplementary Table 15 - Baseline characteristics of the ACE cohort stratified by LOAD status. P values
 are obtained from t-test for continuous variables, and chi-square test for categorical variables. P and FDR
 values <0.05 are highlighted in bold.</li>

Supplementary Table 16 – Forward MR analysis examining the causal effects of all LOAD-associated
 proteins in AGES on AD. P and FDR values <0.05 are highlighted in bold. Abbreviations: OR, odds ratio;</li>
 SE, standard error; eggerPass, passes Egger pleiotropy sensitivity analysis; wmPass, passes weighted

818 median sensitivity analysis

Supplementary Table 17 – Reverse MR analysis examining the causal effects of AD or its genetic liability
on all LOAD-associated proteins in AGES. The primary analysis was performed without the APOE locus
included, but results including the APOE locus are also shown. P and FDR values <0.05 are highlighted in</li>
bold. Abbreviations: OR, odds ratio; SE, standard error; Q\_pval, Cochran's Q p-value for instrument
heterogeneity

Supplementary Table 18 – Replication of reverse MR analysis results in data from Ferkingstad et al. and
Sun et al, examining the causal effects of AD on all AGES-defined LOAD-associated proteins. The analysis
was performed with and without the APOE locus included for instrument selection. One protein, ARL2,
was not available in the Sun et al. data. P and FDR values <0.05 are highlighted in bold. Abbreviations: SE,</li>
standard error.

Supplementary Table 19 – Proteins associated with prevalent or incident LOAD in AGES that are also
 associated with AD in either CSF or brain. AGES results are shown for all outcomes and models from
 which significant proteins were obtained from. P and FDR values <0.05 are highlighted in bold.</li>
 Abbreviations: HR, Hazard ratio; CI, Confidence Interval; OR, Odds ratio; SE, Standard error.
 Supplementary Table 20 – Protein association with AD in brain when adjusting for APOE-e4 count (0,1,2)

in multinominal logistic regression. Data was obtained from Johnson et al, Nature Neuroscience 2022.
Proteins with any association to LOAD in AGES and available data are included in the table, and the HR
for incident LOAD in Model 1 and Model 2 are shown for comparison and used to evaluate directional
consistency. P and FDR values <0.05 are highlighted in bold. Abbreviations: OR, Odds ratio; SE, Standard</li>
error; APOE, APOE-dependent proteins in AGES.

839 Supplementary Table 21 – Serum, CSF and brain protein module membership for all proteins measured
840 in serum in the AGES study.

- 841 CSF modules were obtained from an extended analysis compared to Dammer et al, Alzheimer's Research
- 842 & Therapy 2022 (manuscript in preparation), and brain modules from Johnson et al., Nature
- 843 Neuroscience 2022. The same protein can occur in more than one module when measured by more than
- one aptamer (serum and CSF), by different platforms (CSF) or when different peptides are quantified by
- 845 MS (CSF, brain)
- 846 **Supplementary Table 22** Overlaps between protein modules (defined from serum, CSF or brain) and
- 847 proteins associated with AD (in serum, protein or brain) tested by Fisher's exact test. Serum modules
- 848 were additionally tested for overlap with proteins detected/measured in CSF and brain, irrespective of
- their AD association. FDR was calculated using Benjamini-Hochberg. P and FDR values <0.05 are
- highlighted in bold. Abbreviations: OR, odds ratio; CI, Confidence Interval.

## 851 References

- Gatz, M. *et al.* Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* 63, 168–174 (2006).
- Reitz, C., Rogaeva, E. & Beecham, G. W. Late-onset vs nonmendelian early-onset Alzheimer
   disease: A distinction without a difference? *Neurol Genet* 6, (2020).
- 856 3. Rajan, K. B. *et al.* Population Estimate of People with Clinical AD and Mild Cognitive Impairment in
  857 the United States (2020–2060). *Alzheimers Dement* **17**, 1966 (2021).
- 4. van Dyck, C. H. *et al.* Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*388, 9–21 (2023).
- 860 5. Mintun, M. A. *et al.* Donanemab in Early Alzheimer's Disease. *New England Journal of Medicine*861 384, 1691–1704 (2021).
- 862 6. Sattlecker, M. *et al.* Longitudinal Protein Changes in Blood Plasma Associated with the Rate of
  863 Cognitive Decline in Alzheimer's Disease. *Journal of Alzheimer's Disease* 49, 1105–1114 (2016).
- Kiddle, S. J. *et al.* Candidate Blood Proteome Markers of Alzheimer's Disease Onset and
  Progression: A Systematic Review and Replication Study. *Journal of Alzheimer's Disease* 38, 515–
  531 (2014).
- 867 8. Sattlecker, M. *et al.* Alzheimer's disease biomarker discovery using SOMAscan multiplexed
  868 protein technology. *Alzheimer's & Dementia* **10**, 724–734 (2014).

869 9. O'Bryant, S. E. *et al.* A Serum Protein-Based Algorithm for the Detection of Alzheimer's Disease.
870 *Arch Neurol* 67, 1077 (2010).

871	10.	ljsselstijn, L. et al. Serum levels of pregnancy zone protein are elevated in presymptomatic
872		alzheimer's disease. <i>J Proteome Res</i> <b>10</b> , 4902–4910 (2011).

- Ray, S. *et al.* Classification and prediction of clinical Alzheimer's diagnosis based on plasma
  signaling proteins. *Nature Medicine 2007 13:11* 13, 1359–1362 (2007).
- Henkel, A. W. *et al.* Multidimensional plasma protein separation technique for identification of
  potential Alzheimer's disease plasma biomarkers: A pilot study. *J Neural Transm* 119, 779–788
  (2012).
- 13. Choi, J., Malakowsky, C. A., Talent, J. M., Conrad, C. C. & Gracy, R. W. Identification of oxidized
  plasma proteins in Alzheimer's disease. *Biochem Biophys Res Commun* 293, 1566–1570 (2002).
- 14. Cutler, P. *et al.* Proteomic identification and early validation of complement 1 inhibitor and
  pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human
  plasma. *Proteomics Clin Appl* 2, 467–477 (2008).
- Hye, A. *et al.* Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* 129, 3042–3050
  (2006).
- 16. Doecke, J. D. *et al.* Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. *Arch Neurol* 69, 1318 (2012).
- Kiddle, S. J. *et al.* Candidate Blood Proteome Markers of Alzheimer's Disease Onset and
  Progression: A Systematic Review and Replication Study. *Journal of Alzheimer's Disease* 38, 515–
  531 (2014).
- Walker, K. A. *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways
  associated with dementia risk. *Nature Aging 2021 1:5* 1, 473–489 (2021).
- 89219.Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related893dementias. Nature Genetics 2022 1–25 (2022) doi:10.1038/s41588-022-01024-z.
- 89420.Khani, M., Gibbons, E., Bras, J. & Guerreiro, R. Challenge accepted: uncovering the role of rare895genetic variants in Alzheimer's disease. *Mol Neurodegener* **17**, 3 (2022).
- 896 21. Frisoni, G. B. *et al.* The prevalence of apoE-ε4 in Alzheimer's disease is age dependent. *J Neurol* 897 *Neurosurg Psychiatry* 65, 103 (1998).
- 898 22. Gharbi-Meliani, A. *et al.* The association of APOE ε4 with cognitive function over the adult life
  899 course and incidence of dementia: 20<sup>2</sup> years follow-up of the Whitehall II study. *Alzheimers Res*900 *Ther* 13, (2021).
- 23. Corder, E. H. *et al.* Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's
  Disease in Late Onset Families. *Science (1979)* 261, 921–923 (1993).

903 904	24.	Gudjonsson, A. <i>et al.</i> A genome-wide association study of serum proteins reveals shared loci with common diseases. <i>Nature Communications 2022 13:1</i> <b>13</b> , 1–13 (2022).
905 906	25.	Sun, B. B. <i>et al.</i> Genomic atlas of the human plasma proteome. <i>Nature 2018 558:7708</i> <b>558</b> , 73–79 (2018).
907 908	26.	Emilsson, V. <i>et al.</i> Co-regulatory networks of human serum proteins link genetics to disease. <i>Science</i> <b>361</b> , (2018).
909 910	27.	Emilsson, V. <i>et al.</i> Coding and regulatory variants are associated with serum protein levels and disease. <i>Nature Communications 2022 13:1</i> <b>13</b> , 1–11 (2022).
911 912 913	28.	Cruchaga, C. <i>et al.</i> Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and informs causal proteins for Alzheimer's disease. <i>Res Sq</i> (2023) doi:10.21203/rs.3.rs-2814616/v1.
914 915	29.	Yang, C. <i>et al.</i> Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. <i>Nat Neurosci</i> <b>24</b> , 1302–1312 (2021).
916 917	30.	Harris, T. B. <i>et al.</i> Age, Gene/Environment Susceptibility – Reykjavik Study: Multidisciplinary Applied Phenomics. <i>Am J Epidemiol</i> <b>165</b> , 1076 (2007).
918	31.	Uhlén, M. <i>et al.</i> Proteomics. Tissue-based map of the human proteome. <i>Science</i> <b>347</b> , (2015).
919 920	32.	Li, T. <i>et al.</i> A scored human protein–protein interaction network to catalyze genomic interpretation. <i>Nature Methods 2016 14:1</i> <b>14</b> , 61–64 (2016).
921 922	33.	Postmus, I. <i>et al.</i> Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nat Commun</i> <b>5</b> , (2014).
923 924	34.	Marucci, G. <i>et al.</i> Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. <i>Neuropharmacology</i> <b>190</b> , (2021).
925 926	35.	Ferkingstad, E. <i>et al.</i> Large-scale integration of the plasma proteome with genetics and disease. <i>Nat Genet</i> <b>53</b> , 1712–1721 (2021).
927 928 929	36.	Dammer, E. B. <i>et al.</i> Proteomic Network Analysis of Alzheimer's Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE 124 Genotype and Atomoxetine Treatment. <i>medRxiv</i> 2023.10.29.23297651 (2023) doi:10.1101/2023.10.29.23297651.
930 931 932	37.	Johnson, E. C. B. <i>et al.</i> Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. <i>Nature Neuroscience 2022 25:2</i> <b>25</b> , 213–225 (2022).
933 934 935	38.	Dammer, E. B. <i>et al.</i> Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. <i>Alzheimers Res Ther</i> <b>14</b> , (2022).

936 937	39.	Porter, T. <i>et al.</i> Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Pers Med Psychiatry</i> <b>7–8</b> , 14–20 (2018).
938 939	40.	Zhou, M. <i>et al.</i> Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Clin Proteomics</i> <b>17</b> , 1–14 (2020).
940 941	41.	Lourenço, F. C. <i>et al.</i> Netrin-1 interacts with amyloid precursor protein and regulates amyloid- beta production. <i>Cell Death Differ</i> <b>16</b> , 655–663 (2009).
942 943	42.	Zetterberg, H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. <i>Neuron <b>91</b>, 1–</i> 3 (2016).
944 945	43.	Graham, N. S. N. <i>et al.</i> Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. <i>Sci Transl Med</i> <b>13</b> , (2021).
946 947	44.	Wolters, F. <i>et al.</i> Von Willebrand Factor and the Risk of Dementia: A Population-Based Study (P1.092). <i>Neurology</i> <b>86</b> , (2016).
948 949	45.	Johnson, E. C. B. <i>et al.</i> Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease. <i>Nat Med</i> (2023) doi:10.1038/s41591-023-02476-4.
950 951	46.	Sattlecker, M. <i>et al.</i> Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. <i>Alzheimer's &amp; Dementia</i> <b>10</b> , 724–734 (2014).
952 953 954	47.	Lindbohm, J. V. <i>et al.</i> Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. <i>Alzheimer's &amp; Dementia</i> <b>18</b> , 612 (2022).
955 956	48.	Eldjarn, G. H. <i>et al.</i> Large-scale plasma proteomics comparisons through genetics and disease associations. <i>Nature</i> <b>622</b> , 348–358 (2023).
957 958	49.	Sebastiani, P. <i>et al.</i> A serum protein signature of APOE genotypes in centenarians. <i>Aging Cell</i> <b>18</b> , e13023 (2019).
959	50.	Uhlén, M. <i>et al.</i> Proteomics. Tissue-based map of the human proteome. <i>Science</i> <b>347</b> , (2015).
960 961	51.	Buniello, A. <i>et al.</i> The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. <i>Nucleic Acids Res</i> <b>47</b> , D1005–D1012 (2019).
962 963	52.	Jun, G. <i>et al.</i> A NOVEL ALZHEIMER DISEASE LOCUS LOCATED NEAR THE GENE ENCODING TAU PROTEIN. <i>Mol Psychiatry</i> <b>21</b> , 108 (2016).
964 965	53.	Okbay, A. <i>et al.</i> Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. <i>Nat Genet</i> <b>54</b> , 437–449 (2022).
966 967	54.	Brouwer, R. M. <i>et al.</i> Genetic variants associated with longitudinal changes in brain structure across the lifespan. <i>Nature Neuroscience 2022 25:4</i> <b>25</b> , 421–432 (2022).

968 55. 969	Davies, G. <i>et al.</i> Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. <i>Nat Commun</i> <b>9</b> , (2018).
970 56. 971	Wang, H. <i>et al.</i> Genome-wide interaction analysis of pathological hallmarks in Alzheimer's disease. <i>Neurobiol Aging</i> <b>93</b> , 61–68 (2020).
972 57. 973 974	Tin, A. <i>et al.</i> Proteomic Analysis Identifies Circulating Proteins Associated With Plasma Amyloid $\beta$ and Incident Dementia. <i>Biological Psychiatry Global Open Science</i> (2022) doi:10.1016/J.BPSGOS.2022.04.005.
975 58. 976	Tanzi, R. E. <i>et al.</i> Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. <i>Science</i> <b>235</b> , 880–884 (1987).
977 59. 978	Bai, Z. <i>et al.</i> Distinctive RNA Expression Profiles in Blood Associated with Alzheimer's Disease after Accounting for White Matter Hyperintensities. <i>Alzheimer Dis Assoc Disord</i> <b>28</b> , 226–233 (2014).
979 60. 980 981	Wang, D. <i>et al.</i> Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease. <i>Pharmacol Biochem Behav</i> <b>107</b> , 48–57 (2013).
982 61. 983 984	Rayaprolu, S. <i>et al.</i> Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer's disease. <i>Mol Neurodegener</i> <b>15</b> , 28 (2020).
985 62. 986	Chen, HH. <i>et al</i> . Genetically regulated expression in late-onset Alzheimer's disease implicates risk genes within known and novel loci. <i>Transl Psychiatry</i> <b>11</b> , 618 (2021).
987 63. 988	Sügis, E. <i>et al.</i> HENA, heterogeneous network-based data set for Alzheimer's disease. <i>Sci Data</i> <b>6</b> , 151 (2019).
989 64. 990	Zetterberg, H. <i>et al.</i> Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurol</i> <b>73</b> , 60 (2016).
991 65. 992 993	Bernardini, S. <i>et al.</i> Glutathione S-Transferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E ε4 Allele. <i>Clin Chem</i> <b>51</b> , 944–951 (2005).
994 66. 995 996	Pinhel, M. A. S. <i>et al.</i> Glutathione S-transferase variants increase susceptibility for late-onset Alzheimer's disease: association study and relationship with apolipoprotein E 🛛 4 allele. <i>Clin Chem Lab Med</i> <b>46</b> , (2008).
997 67. 998 999	Sigurdsson, S. <i>et al.</i> Incidence of Brain Infarcts, Cognitive Change, and Risk of Dementia in the General Population: The AGES-Reykjavik Study (Age Gene/Environment Susceptibility-Reykjavik Study). <i>Stroke</i> <b>48</b> , 2353–2360 (2017).

1000 1001	68.	Jørgensen, L. M., El Kholy, K., Damkjær, K., Deis, A. & Schroll, M. »RAI«🛛- Et internationalt system til vurdering af beboere på plejehjem. <i>Ugeskr Laeger</i> <b>159</b> , 6371–6376 (1997).
1002 1003 1004	69.	Gudnason V, S. J. S. L. H. S. S. G. Association of apolipoprotein E polymorphism with plasma levels of high density lipoprotein and lipoprotein(a), and effect of diet in healthy men and women. <i>NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES</i> <b>3</b> , 136–141 (1993).
1005 1006	70.	Levey, A., Greene, T., Kusek, J. & Beck, G. A simplified equation to predict glomerular filtration rate from serum creatinine. <i>Journal of the American Society of Nephrology</i> <b>11</b> , 155A (2000).
1007 1008	71.	Gudmundsdottir, V. <i>et al.</i> Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes. <i>Diabetes <b>69</b>, 1843 (2020).</i>
1009 1010	72.	Lamb, J. R., Jennings, L. L., Gudmundsdottir, V., Gudnason, V. & Emilsson, V. It's in Our Blood: A Glimpse of Personalized Medicine. <i>Trends Mol Med</i> <b>27</b> , 20–30 (2021).
1011 1012	73.	Gold, L. <i>et al.</i> Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. doi:10.1371/journal.pone.0015004.
1013 1014 1015	74.	Tuck, M. K. <i>et al.</i> Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group. <i>J Proteome Res</i> <b>8</b> , 113–117 (2009).
1016 1017	75.	Jessen, F. <i>et al.</i> A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's &amp; Dementia</i> <b>10</b> , 844–852 (2014).
1018 1019	76.	Lopez, O. L. <i>et al.</i> Risk Factors for Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. <i>Arch Neurol</i> <b>60</b> , 1394 (2003).
1020 1021	77.	Petersen, R. C. <i>et al.</i> Mild cognitive impairment: a concept in evolution. <i>J Intern Med</i> <b>275</b> , 214– 228 (2014).
1022	78.	Petersen, R. C. et al. Mild Cognitive Impairment. Arch Neurol 56, 303 (1999).
1023 1024	79.	Jack, C. R. <i>et al.</i> NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's &amp; Dementia</i> 14, 535–562 (2018).
1025 1026	80.	Orellana, A. <i>et al.</i> Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>Int J Mol Sci</i> <b>23</b> , 6891 (2022).
1027 1028 1029 1030	81.	Rodriguez-Gomez, O. <i>et al.</i> FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS. <i>J Prev Alzheimers Dis</i> 1–9 (2016) doi:10.14283/jpad.2016.122.

1031 1032 1033	82.	Moreno-Grau, S. <i>et al.</i> Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's &amp; Dementia</i> <b>15</b> , 1333–1347 (2019).
1034 1035 1036	83.	Vanderstichele, H. <i>et al.</i> Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's &amp; Dementia</i> <b>8</b> , 65–73 (2012).
1037 1038	84.	Candia, J., Daya, G. N., Tanaka, T., Ferrucci, L. & Walker, K. A. Assessment of variability in the plasma 7k SomaScan proteomics assay. <i>Sci Rep</i> <b>12</b> , 17147 (2022).
1039 1040	85.	Therneau, T., Crowson, C. & Clinic, M. Using Time Dependent Covariates and Time Dependent Coefficients in the Cox Model. (2014).
1041 1042	86.	Gottesman, R. F. <i>et al.</i> Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. <i>JAMA Neurol</i> <b>74</b> , 1246 (2017).
1043 1044	87.	Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. <i>OMICS</i> <b>16</b> , 284 (2012).
1045 1046	88.	Korotkevich, G. <i>et al.</i> Fast gene set enrichment analysis. <i>bioRxiv</i> 060012 (2021) doi:10.1101/060012.
1047 1048	89.	Subramanian, A. <i>et al.</i> Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. <i>Proc Natl Acad Sci U S A</i> <b>102</b> , 15545–15550 (2005).
1049 1050	90.	Aguet, F. <i>et al.</i> The GTEx Consortium atlas of genetic regulatory effects across human tissues. <i>Science</i> <b>369</b> , 1318 (2020).
1051 1052	91.	Beach, T. G. <i>et al.</i> Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. <i>Neuropathology</i> <b>35</b> , 354–389 (2015).
1053 1054	92.	Bennett, D. A. <i>et al.</i> Religious Orders Study and Rush Memory and Aging Project. <i>Journal of Alzheimer's Disease</i> <b>64</b> , S161–S189 (2018).
1055 1056	93.	Jack, C. R. <i>et al.</i> NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's &amp; Dementia</i> <b>14</b> , 535–562 (2018).
1057 1058 1059	94.	Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. <i>Stat Med</i> <b>35</b> , 1880 (2016).
1060		













M1 Nucleus/Transcription

Serum – LOAD APOE independent Serum – LOAD APOE dependent

CSF - AD Brain – AD

Serum – LOAD

Serum – LOAD Serum – LOAD APOE independent Serum – LOAD APOE dependent Brain – AD CSF – AD

SMOC

--

1.2

SMOC1

1.2

OR 15+

10

5 3

2

1

0

Tissue

Brain

CSF

Serum

\*\* FDR < 0.05

**\*** P < 0.05

Brain Brain – AD

CSF – AD CSF

Serum – LOAD APOE independent Serum – LOAD APOE dependent Serum – LOAD

M21 Immune

LOAD associated serum proteins 341 incident and 10 prevalent "LOAD associated aptamers out of 4782 tested.

3

Protein interaction partners The APOE-dependent proteins have 365 protein interaction partners. They are enriched for Alzheimer's specific terms. Two protein partners, APP and MAPK3, had a causal association with LOAD.

APOE-dependent proteins 17 aptamers are associated with incident LOAD in an APOE-ε4 dependent manner. They are enriched for oligodendrocyte markers. A subset are causally affected by LOAD.

#### Protein modules

The LOAD associated proteins we find in serum are detected in AD inflicted brain and CSF. Proteins from **brain module M42** are associated with AD in serum, CSF and brain.

# APOE-dependent proteins and cholesterol

The APOE-dependent proteins are associated with cholesterol in an APOE-ε4 independent manner. However their LOAD association is not mediated by circulating cholesterol levels.

APOE-independent proteins 140 aptamers are associated with incident LOAD independently of APOE-ε4 status. They are enriched for neuron development and overlap with Alzheimer's protein signatures in CSF and brain.